U.S. Stem Cell (USRM) 10-K 8 Mar 16 2015 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Mar. 08, 2016	Jun. 30, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	U.S. STEM CELL, INC.
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		2,470,400
Entity Public Float			$ 4,092,862
Amendment Flag	false
Entity Central Index Key	1,388,319
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	Yes
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY

BALANCE SHEETS

BALANCE SHEETS - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 58,372	$ 36,674
Accounts receivable, net	35,032	95,409
Inventory	17,406	0
Prepaid and other	4,832	9,255
Total current assets	115,642	141,338
Property and equipment, net	14,172	12,686
Other assets:
Investments	89,139	40,597
Deposits	10,160	10,160
Total assets	229,113	204,781
Current liabilities:
Accounts payable, including $104,089 and $56,953 to related parties, respectively	1,503,501	1,991,979
Accrued expenses	726,751	2,373,615
Advances, related party	106,505	98,759
Deferred revenue	71,961	13,000
Deposits	465,286	465,286
Promissory note, net of debt discount of $78,864 and $-0- respectively	71,136	1,500,000
Notes payable, related party	1,727,022	2,383,059
Notes payable, net of debt discount of $249,205 and $339,160, respectively	608,502	1,531,812
Derivative liabilities	423,927	741,271
Total current liabilities	5,704,591	11,098,781
Long term debt:
Promissory note, long term portion, net of debt discount of $240,521	1,232,241	0
Notes payable, long term portion	983,727	0
Note payable, long term portion, related party	30,000	0
Total long term debt	2,245,968	0
Total liabilities	7,950,559	11,098,781
Commitments and contingencies	0	0
Stockholders' deficit:
Preferred stock, par value $0.001; 20,000,000 shares authorized, 20,000,000 issued and outstanding	20,000	20,000
Common stock, par value $0.001; 2,000,000,000 shares authorized, 1,813,689 and 581,433 shares issued and 1,728,478 and 581,433 outstanding as of December 31, 2015 and 2014, respectively	1,814	581
Additional paid in capital	114,555,110	109,519,913
Treasury stock, 85,211 shares	(221,996)	0
Accumulated deficit	(122,076,374)	(120,434,494)
Total stockholders' deficit	(7,721,446)	(10,894,000)
Total liabilities and stockholders' deficit	$ 229,113	$ 204,781

BALANCE SHEETS (Parentheticals)

BALANCE SHEETS (Parentheticals) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Promissory note, debt discount (in Dollars)	$ 249,205	$ 339,160
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	20,000,000	20,000,000
Preferred stock, shares outstanding	20,000,000	20,000,000
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	2,000,000,000	2,000,000,000
Common stock, shares issued	1,813,689	581,433
Common stock, shares outstanding	1,728,478	581,433
Treasury stock, shares	85,211
Notes Payable, Other Payables [Member]
Promissory note, debt discount (in Dollars)	$ 240,521
Notes Payable, Other Payables [Member]
Promissory note, debt discount (in Dollars)	$ 78,864	$ 0

STATEMENTS OF OPERATIONS

STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Revenue:
Products	$ 1,356,864	$ 1,155,543
Services	834,313	900,288
Total revenue	2,191,177	2,055,831
Cost of sales	972,957	844,941
Gross profit	1,218,220	1,210,890
Cost and operating expenses:
Research and development	10,000	66,420
Marketing, general and administrative	3,808,628	4,669,432
Depreciation and amortization	5,326	4,490
Total operating expenses	3,823,954	4,740,342
Net loss from operations	(2,605,734)	(3,529,452)
Other income (expenses):
Gain on settlement of debt	2,620,233	2,498,676
Gain on change of fair value of derivative liability	15,095	425,953
Income (loss) from equity investment	38,542	(9,117)
Other income	13,282	0
Interest expense	(1,723,298)	(1,639,571)
Total other income (expenses)	963,854	1,275,941
Net loss before income taxes	(1,641,880)	(2,253,511)
Income taxes (benefit)	0	0
NET LOSS	$ (1,641,880)	$ (2,253,511)
Net loss per common share, basic and diluted (in Dollars per share)	$ (1.80)	$ (4.61)
Weighted average number of common shares outstanding, basic and diluted (in Shares)	912,062	488,667

STATEMENT OF STOCKHOLDERS' EQUI

STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Common Stock Issued in Settlement of Other Debt [Member]Common Stock [Member]	Common Stock Issued in Settlement of Other Debt [Member]Additional Paid-in Capital [Member]	Common Stock Issued in Settlement of Other Debt [Member]	Warrants Issued with Revenue Sharing and Intellectual Property [Member]Additional Paid-in Capital [Member]	Warrants Issued with Revenue Sharing and Intellectual Property [Member]	Common Stock Issued in Settlement of Accounts Payable, Accrued Expenses and Accrued Interest [Member]Common Stock [Member]	Common Stock Issued in Settlement of Accounts Payable, Accrued Expenses and Accrued Interest [Member]Additional Paid-in Capital [Member]	Common Stock Issued in Settlement of Accounts Payable, Accrued Expenses and Accrued Interest [Member]	Common Stock Issued in Settlement of Guarantor Fees [Member]Common Stock [Member]	Common Stock Issued in Settlement of Guarantor Fees [Member]Additional Paid-in Capital [Member]	Common Stock Issued in Settlement of Guarantor Fees [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Receivables from Stockholder [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2013												$ 20,000	$ 380	$ 104,198,527		$ 215,000	$ (118,180,983)	$ (13,747,076)
Balance (in Shares) at Dec. 31, 2013												20,000,000	379,787
Common stock issued in settlement	$ 83	$ 2,230,724	$ 2,230,807										$ 48	1,071,107				$ 1,071,155
Common stock issued in settlement (in Shares)	83,236												48,585					11,918
Common stock issued for services													$ 4	183,987				$ 183,991
Common stock issued for services (in Shares)													3,840					3,840
Common stock issued upon exercise of warrants													$ 12	135,988				$ 136,000
Common stock issued upon exercise of warrants (in Shares)													11,918
Common stock issued as commitment shares in connection with equity purchase agreement													$ 12	(12)
Common stock issued as commitment shares in connection with equity purchase agreement (in Shares)													12,000
Proceeds from issuance of common stock													$ 42	694,583		$ (215,000)		$ 479,625
Proceeds from issuance of common stock (in Shares)													42,067					42,067
Reclassify fair value of derivative liability to equity upon debt extinguishment														128,624				$ 128,624
Fair value of warrants issued				$ 190,262	$ 190,262
Stock based compensation														686,123				686,123
Net loss																	(2,253,511)	(2,253,511)
Balance at Dec. 31, 2014												$ 20,000	$ 581	109,519,913	$ 0		(120,434,494)	(10,894,000)
Balance (in Shares) at Dec. 31, 2014												20,000,000	581,433
Common stock issued in settlement						$ 68	$ 236,818	$ 236,886	$ 24	$ 170,077	$ 170,101		$ 1,038	2,818,666				2,819,704
Common stock issued in settlement (in Shares)						67,944			24,353				1,037,645
Proceeds from issuance of common stock													$ 96	582,712				582,808
Proceeds from issuance of common stock (in Shares)													95,664
Common stock issued in settlement of litigation													$ 7	59,843				$ 59,850
Common stock issued in settlement of litigation (in Shares)													6,650					6,650
Fair value of warrants issued														14,886				$ 14,886
Purchase of 85,211 shares of Company's common stock at average cost of $2.61 per share															(221,996)			(221,996)
Stock based compensation														1,152,195				1,152,195
Net loss																	(1,641,880)	(1,641,880)
Balance at Dec. 31, 2015												$ 20,000	$ 1,814	$ 114,555,110	$ (221,996)		$ (122,076,374)	$ (7,721,446)
Balance (in Shares) at Dec. 31, 2015												20,000,000	1,813,689

STATEMENT OF STOCKHOLDERS' EQU6

STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) (Parentheticals) - Common Stock [Member]	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Purchase of Company's Common Stock, Shares | shares	85,211
Purchase of Company's Common Stock, Average Cost Per Share | $ / shares	$ 2.61

STATEMENTS OF CASH FLOWS

STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (1,641,880)	$ (2,253,511)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	5,326	4,490
Bad debt expense	38,599	28,732
Discount on convertible debt	818,404	546,970
Change in fair value of derivative liability	(15,095)	(425,953)
Gain on settlement of debt	(2,620,233)	(2,498,676)
Common stock issued in settlement of litigation	59,850	0
Non cash payment of interest	528,915	705,710
Change in fair value of warrant modifications	0	148,517
Warrants issued in connection with revenue share agreement	0	190,262
Related party notes payable issued for services rendered	0	800,000
(Income) loss on equity investments	(38,542)	9,117
Common stock issued in exchange for services	0	38,750
Stock based compensation	1,152,195	537,606
(Increase) decrease in:
Receivables	21,778	(104,228)
Inventory	(17,406)	0
Prepaid and other current assets	4,423	(8,471)
Increase (decrease) in:
Accounts payable, including related party accounts payable	434,490	858,437
Accrued expenses	365,525	313,601
Deferred revenue	58,961	0
Net cash used in operating activities	(844,690)	(1,108,647)
CASH FLOWS FROM INVESTING ACTIVITIES:
Payments for investments	(10,000)	(49,714)
Purchase of treasury stock	(221,996)	0
Acquisitions of property and equipment	(2,035)	(8,121)
Net cash used by investing activities	(234,031)	(57,835)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, net	582,808	479,625
Proceeds from related party advances	13,606	33,760
Proceeds from exercise of stock options and warrants	0	136,000
Proceeds from notes payable	770,052	740,500
Repayments of notes payable	(266,047)	(232,956)
Net cash provided in financing activities	1,100,419	1,156,929
Net increase (decrease) in cash and cash equivalents	21,698	(9,553)
Cash and cash equivalents, beginning of period	36,674	46,227
Cash and cash equivalents, end of period	58,372	36,674
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Interest paid	321,846	429,569
Income taxes paid	0	0
Non cash financing activities:
Common stock warrant issued in settlement of accounts payable	14,886
Promissory note issued in exchange for subordinated debt and accrued expenses	1,697,762	0
Common Stock Issued in Settlement of Notes Payable [Member]
Non cash financing activities:
Non-cash financing activities, stock issued	926,381	1,367,927
Common Stock Issued in Settlement of Accounts Payable [Member]
Non cash financing activities:
Non-cash financing activities, stock issued	236,886	1,071,155
Common Stock Issued in Settlement of Guarantor Fees [Member]
Non cash financing activities:
Non-cash financing activities, stock issued	170,101	0
Common Stock Issued in Settlement of Related Party Notes and Advances Payable [Member]
Non cash financing activities:
Non-cash financing activities, stock issued	471,101	862,880
Common Stock Issued in Settlement of Legal Fees [Member]
Non cash financing activities:
Non-cash financing activities, stock issued	15,000	0
Common Stock Warrant Issued in Settlement of Accounts Payable [Member]
Non cash financing activities:
Common stock warrant issued in settlement of accounts payable	$ 14,886	$ 0

NOTE 1 - SIGNIFICANT ACCOUNTING

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]	NOTE 1 — SIGNIFICANT ACCOUNTING POLICIES A summary of the significant accounting policies applied in the presentation of the accompanying financial statements follows: Basis and business presentation U.S. Stem Cell, Inc. (the “Company”) was incorporated under the laws of the State of Florida in August, 1999. The Company is in the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Our business includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. To date, the Company has not generated significant sales revenues to cover costs, incurred expenses, and as a result has sustained losses. On October 12, 2015, the Company amended its Articles of Incorporation to change its name from Bioheart, Inc. to U.S. Stem Cell, Inc. and to implement a reverse stock split in the ratio of 1 share for every 1,000 shares of common stock. This amendment was approved and filed of record by the Florida Secretary of State on October 12, 2015, effective on October 19, 2015. FINRA has declared the Company’s 1-for-1,000 reverse stock split market effective as of November 4, 2015. In addition, the ticker symbol was BHRTD for 20 business days from November 4 th Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. At the time of each transaction, management assesses whether the fee associated with the transaction is fixed or determinable and whether or not collection is reasonably assured. The assessment of whether the fee is fixed or determinable is based upon the payment terms of the transaction. Collectability is assessed based on a number of factors, including past transaction history with the client and the creditworthiness of the client. The Company’s primary source of revenue are from the sale of test kits and equipment, training services, patient treatments and laboratory services, and cell banking. Revenues for test kits and equipment sold are not recorded until test kits and equipment are delivered. During 2014, the Company had revenue sharing arrangements for the sale of goods whereby the Company was the primary obligor, set pricing with the customers and bared all associated credit risks with the customers. Sales under revenue share arrangements are recorded as gross sales and any portion shared with third parties under such arrangements are classified as selling expense due to the nature of the marketing activities performed by the third party. All revenue sharing arrangements were terminated in November 2014. Revenues from trainings are recognized when the training occurs. Any cash received as a deposit for trainings are recorded by the company as a liability. Patient treatments and laboratory services revenue are recognized when those services have been completed or satisfied. Revenues for cell banking sales are accounted for as Multiple-Element Arrangements under ASC 605-10 which incorporates Accounting Standards Codification subtopic 605-25, Multiple-Element Arrangements (“ASC 605-25”). ASC 605-25 addresses accounting for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets. Because the Company sells its services separately, on more than a limited basis and at a price within a narrow range, the Company was able to allocate revenue based on vendor-specific objective evidence of fair value (VSOE). At December 31, 2015 and 2014, the Company had deferred revenues of $71,961 and $13,000, respectively. Estimates The preparation of the financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, revenues and expenses and certain disclosures. The most significant estimates are those used in determination of derivative liabilities and stock compensation. Accordingly, actual results could differ from those estimates. Cash The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash. Accounts Receivable Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. Allowance for Doubtful Accounts Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. As of December 31, 2015 and 2014, allowance for doubtful accounts was $-0-. Inventories Inventories are stated at the lower of cost or market with cost being determined on a first-in, first-out (FIFO) basis. The Company writes down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. During 2015 not there were no inventory write-downs. Investments The Company has adopted Accounting Standards Codification subtopic 323-10, Investments-Equity Methods and Joint Ventures (“ASC 323-10) which requires the accounting for investments where the Company can exert significant influence, but not control of a joint venture or equity investment. The Company accounted for its 33 percent ownership of U.S. Stem Cell Clinic, LLC utilizing the equity method of accounting. Long-Lived Assets The Company follows FASB ASC 360-10-15-3, “Impairment or Disposal of Long-lived Assets,” which established a “primary asset” approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. The Company determined that there was no impairment on its long-lived assets during 2015 and 2014. Property and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 15 years. Income Taxes The Company has adopted Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statement or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Temporary differences between taxable income reported for financial reporting purposes and income tax purposes consist primarily of derivative liability and stock compensation accounting versus tax differences. Comprehensive Income The Company does not have any items of comprehensive income in any of the periods presented. Net Loss per Common Share, basic and diluted The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted income (loss) per share as of December 31, 2015 and 2014 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows: 2015 2014 Convertible notes payable 677,540 901,796 Options to purchase common stock 555,820 66,933 Warrants to purchase common stock 139,367 150,620 Totals 1,372,727 1,119,349 Stock Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the statements of operations, as if such amounts were paid in cash. As of December 31, 2015, there were outstanding stock options to purchase 555,820 shares of common stock, 511,660 shares of which were vested. (see Note 12) Treasury Stock The Company use the cost method when it purchases its own common stock as treasury shares and displays treasury stock as a reduction of shareholders’ equity. Concentrations of Credit Risk The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Generally, the Company’s cash and cash equivalents in interest-bearing accounts does not exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management. As of December 31, 2015, three customers represented 32%, 18% and 16%, an aggregate of 66% of the Company’s accounts receivable. As of December 31, 2014, two customers represented 38% and 17%, an aggregate of 55%, of the Company’s accounts receivable. The Company’s revenues earned from sale of products and services for the year ended December 31, 2015 did not include any customers representing 10% or more of the Company’s total revenues. For the year ended December 31, 2014, Company’s revenues earned from sale of products and services included 10% of the Company’s total revenues from one customer. Reliance on Key Personnel and Consultants The Company has four full-time employees and one part-time employees. The Company is heavily dependent on the continued active participation of its two current executive officers, one employee and key consultants. The loss of any of the senior management or key consultants could significantly and negatively impact the business until adequate replacements can be identified and put in place. Research and Development The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $10,000 and $66,420 for the years ended December 31, 2015 and 2014, respectively. Fair Value Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value. Derivative Instrument Liability The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At December 31, 2015 and 2014, the Company did not have any derivative instruments that were designated as hedges. At December 31, 2015 and 2014, the Company had outstanding convertible notes and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions. (See Note 8 and Note 10). Reclassification Certain reclassifications have been made to prior periods’ data to conform with the current year’s presentation. These reclassifications had no effect on reported income or losses. Recent Accounting Pronouncements In November 2015, the FASB issued (ASU) 2015-17, Balance Sheet Classification of Deferred Taxes. In January 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU) 2016-01, which amends the guidance in U.S. GAAP on the classification and measurement of financial instruments. Changes to the current guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The new standard is effective for fiscal years and interim periods beginning after December 15, 2017, and upon adoption, an entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company is currently evaluating the impact of adopting this guidance. There were other various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.

NOTE 2 - GOING CONCERN AND MANA

NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS	12 Months Ended
	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	NOTE 2 – GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements during year ended December 31, 2015, the Company incurred net losses of $1,641,880 and used $844,690 in cash for operating activities. These factors among others may indicate that the Company will be unable to continue as a going concern for a reasonable period of time. The Company’s existence is dependent upon management’s ability to develop profitable operations and to obtain additional funding sources. There can be no assurance that the Company’s financing efforts will result in profitable operations or the resolution of the Company’s liquidity problems. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern. The Company’s ability to obtain additional debt financing and/or alternative arrangements, with the Guarantors or otherwise, may be limited by the amount of, terms and restrictions of our then current debt. Accordingly, until such time, we will generally be restricted from, among other things, incurring additional indebtedness or liens, with limited exceptions. Additional debt financing, if available, may involve restrictive covenants that limit or further limit our operating and financial flexibility and prohibit us from making distributions to shareholders.

NOTE 3 - INVESTMENTS

NOTE 3 - INVESTMENTS	12 Months Ended
	Dec. 31, 2015
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments and Joint Ventures Disclosure [Text Block]	NOTE 3 — INVESTMENTS The investment recorded is comprised of a 33% ownership of U.S. Stem Cell Clinic, LLC, accounted for using the equity method of accounting. The investments in 2014 and 2015 of cash and expenses paid on U.S. Stem Cell Clinic, LLC’s behalf were an aggregate of $59,714. The Company’s 33% income (loss) earned by U.S. Stem Cell Clinic, LLC of $38,542 and $(9,117) for the year ended December 31, 2015 and 2014, respectively, (inception to date income of $29,425) was recorded as other income/expense in the Company’s Statement of Operations in the appropriate periods and increased the carrying value of the investment to $89,139. At December 31, 2015 and 2014, accounts receivable for sales of test kits to U.S. Stem Cell Clinic, LLC was $5,946 and $-0-; revenues earned from sales to U.S. Stem Clinic, LLC for 2015 and 2014 were $182,922 and $-0-, respectively.

NOTE 4 - PROPERTY AND EQUIPMENT

NOTE 4 - PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	NOTE 4 — PROPERTY AND EQUIPMENT Property and equipment as of December 31, 2015 and 2014 is summarized as follows: 2015 2014 Laboratory and medical equipment $ 353,253 $ 352,358 Furniture, fixtures and equipment 130,410 125,634 Computer equipment 48,788 47,647 Leasehold improvements 362,046 362,046 894,497 887,685 Less accumulated depreciation and amortization (880,325 ) (874,999 ) $ 14,172 $ 12,686 Property and equipment are recorded on the basis of cost. For financial statement purposes, property, plant and equipment are depreciated using the straight-line method over their estimated useful lives. Expenditures for repair and maintenance which do not materially extend the useful lives of property and equipment are charged to operations. When property or equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts with the resulting gain or loss reflected in operations. Management periodically reviews the carrying value of its property and equipment for impairment in accordance with the guidance for impairment of long lived assets.

NOTE 5 - ACCRUED EXPENSES

NOTE 5 - ACCRUED EXPENSES	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 5 — ACCRUED EXPENSES Accrued expenses consisted of the following as of December 31, 2015 and 2014: 2015 2014 Amounts payable to the Guarantors of the Company’s loan agreement with Bank of America and Seaside Bank, including fees and interest $ 64,199 $ 1,533,217 Interest payable on notes payable 467,664 685,575 Vendor accruals and other 147,244 120,836 Employee commissions, compensation, etc. 47,644 33,987 $ 726,751 $ 2,373,615 In June 2000, the Company had entered into an agreement with William Beaumont Hospital, or WBH, pursuant to which WBH granted the Company a worldwide, exclusive, non-sublicenseable license to two U.S. method patents covering the inducement of human adult myocardial cell proliferation in vitro, or the WBH IP. The term of the agreement was for the life of the patents, which expire in 2015. The Company did not use this license in any of their technologies or made any payments to WBH other than the initial payment to acquire the license. On April 2, 2014, the Company received confirmation from WBH that it has no obligation under the patent license agreement and WBH agreed to terminate the patent license agreement pursuant to a termination letter dated March 3, 2014. Accordingly, the Company recognized approximately $2,122,130 in settlement of debt which represents the accumulative accrual and related interest from past years under the 2000 patent license agreement during the year ended December 31, 2014. During the year ended December 31, 2014, the Company issued an aggregate of 48,585 shares of its common stock in settlement of outstanding accounts payable and accrued expenses. In connection with the issuance, the Company incurred $120,656 net gain in settlement of debt. During the year ended December 31, 2015, the Company issued an aggregate of 67,944 shares of its common stock in settlement of outstanding accounts payable and accrued interest. In connection with the issuance, the Company incurred $144,669 gain in settlement of debt. During the year ended December 31, 2015, the Company incurred a gain of $513,940 in relief of accounts payable. During the year ended December 31, 2015, the Company issued an aggregate of 24,353 shares of its common stock in settlement of accumulative outstanding amounts due to Guarantors of the Company of $961,124. In connection with the issuance, the Company incurred a $791,024 gain in settlement of debt. During the year ended December 31, 2015, the Company settled an outstanding subordinated debt, related accrued interest and accounts payable due to the guarantor by issuing a five year, non-interest bearing note payable. (See Note 8). In connection with the note issuance, the Company settled $624,737 of outstanding guarantor fees.

NOTE 6 - STANDBY EQUITY DISTRIB

NOTE 6 - STANDBY EQUITY DISTRIBUTION AGREEMENT	12 Months Ended
	Dec. 31, 2015
Standby Equity Distribution Agreement [Abstract]
Standby Equity Distribution Agreement [Text Block]	NOTE 6 – STANDBY EQUITY DISTRIBUTION AGREEMENT Greystone Capital Partners On November 2, 2011, the Company and Greystone Capital Partners (“Greystone”) entered into a Standby Equity Distribution Agreement (the “Agreement”). Pursuant to the Agreement, Greystone has agreed to provide the Company with up to $1,000,000 of funding for the 24-month period following the date February 10, 2012, the registration statement of the Company’s common stock was declared effective by the SEC (the “Equity Line”). During this 24-month period, commencing on the date on which the SEC first declared the registration statement effective, the Company may request a draw down under the Equity Line by which the Company would sell shares of its common stock to Greystone, which is obligated to purchase the shares under the Agreement. For each share of the Company common stock purchased under the Agreement, Greystone will pay eighty percent (80%) of the average of the lowest daily volume weighted average price for five consecutive trading days immediately preceding Advance Notice (the “Valuation Period”) commencing the date an Advance Notice (the “Advance Notice”) is delivered to Greystone in a manner provided by the Agreement. Subject to certain limitations and floor price reductions, the Company may, at its sole discretion, issue a Put Notice to Greystone and Greystone will then be irrevocably bound to acquire such shares. The registration statement of the Company’s common stock pursuant to the Agreement was declared effective on February 10, 2012 and a Post-Effective Amendment was declared effective on May 7, 2013. On December 1, 2012, the parties to the Equity Line agreed that the Purchase Price be adjusted to seventy-five percent (75%) of the lowest daily volume weighted average price of the Common Stock as quoted by Bloomberg, LP, during the five (5) consecutive Trading Days (as such term is defined in the Equity Line) immediately subsequent to the date of the relevant Advance Notice. No common stock were issued during the year ended December 31, 2014. The Agreement automatically terminated on the first of April, 2014 (the first day of the month next following the second (2 nd

NOTE 7 - STOCK PURCHASE AGREEME

NOTE 7 - STOCK PURCHASE AGREEMENT	12 Months Ended
	Dec. 31, 2015
Stock Purchase Agreement Disclosure [Abstract]
Stock Purchase Agreement Disclosure [Text Block]	NOTE 7 – STOCK PURCHASE AGREEMENT On October 23, 2014, the Company, entered into a common stock purchase agreement (the “Purchase Agreement”) with Magna Equities II, LLC, a New York limited liability company (the “Investor”). The Purchase Agreement provides that, upon the terms and subject to the conditions set forth therein, the Investor is committed to purchase up to $3,000,000 (the “Total Commitment”) worth of the Company’s common stock, $0.001 par value (the “Shares”), over the 24-month term of the Purchase Agreement. From time to time over the term of the Purchase Agreement, commencing on the trading day immediately following the date on which the initial registration statement was declared effective by the Securities and Exchange Commission (the “Commission”), the Company may provide the Investor with a draw down notice to purchase a specified dollar amount of Shares, with each draw down subject to certain limitations. The Company may not deliver any Draw Down Notice to the Investor if the Initial Purchase Price with respect to the Shares subject to such Draw Down Notice is less than $2.50 as of the date the applicable Draw Down Notice is received by the Investor (the “Draw Down Exercise Date”). The applicable Initial Purchase Price, the “Initial Purchase Price”, is defined as a price equal to 93% of the lowest of (i) the arithmetic average of the three lowest daily volume weighted average prices for the Company’s common stock (the “ VWAP In 2014, the Company paid to the Investor as a commitment fee for entering into the Purchase Agreement equal an aggregate of to 12,000 shares of the Company’s common stock. During the year ended December 31, 2015, the Company issued an aggregate of 87,812 shares of its common stock in exchange for $521,538 under the Purchase Agreement. (See Note 11)

NOTE 8 - NOTES PAYABLE

NOTE 8 - NOTES PAYABLE	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	NOTE 8 — NOTES PAYABLE Notes payable were comprised of the following as of December 31, 2015 and 2014: 2015 2014 Seaside Bank note payable. $ 980,000 $ 980,000 Hunton & Williams notes payable 384,972 384,972 Asher notes payable - 151,000 Daniel James Management notes payable 75,000 75,000 Fourth Man, LLC notes payable 77,450 75,000 Magna Group notes payable 125,000 205,000 Power Up Lending Group notes payable 194,235 - Equipment finance lease 4,777 - Total notes payable 1,841,434 1,870,972 Less unamortized debt discount (249,205 ) (339,160 ) Total notes payable net of unamortized debt discount 1,592,229 1,531,812 Less current portion (608,502 ) (1,531,812 ) Long term portion $ 983,727 $ - Seaside Bank On October 25, 2010, the Company entered into a Loan Agreement with Seaside National Bank and Trust for a $980,000 loan at 4.25% per annum interest that was used to refinance the Company’s loan with Bank of America. The obligation is guaranteed by certain shareholders of the Company. The Company renewed the loan with Seaside National Bank and Trust during the first quarter of 2016 to extend the maturity date to January 11, 2018. Hunton & Williams Notes At December 31, 2015 and 2014, the Company has two outstanding notes payable with interest at 8% per annum due at maturity. The two notes, $61,150 and $323,822, are payable in one balloon payment upon the date the Noteholder provides written demand, however the Company is not obligated to make payments until the Northstar (or successor) Loan is paid off. Asher Notes 2014 Notes During the year ended December 31, 2014, the Company entered into a Securities Purchase Agreements with Asher Enterprises, Inc. (“Asher”) or affiliates, for the sale of 8% convertible notes in aggregate principal amount of $334,000 (the “Asher Notes”). The Asher Notes bear interest at the rate of 8% per annum. As of December 31, 2014, all interest and principal must be repaid nine months from the issuance date, with the last note being due August 12, 2015. The Notes are convertible into common stock, at Asher’s option, at a 45% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Asher Notes. These embedded derivatives included certain conversion features and a reset provision. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Asher Notes and to fair value as of each subsequent reporting date, which at December 31, 2014 was $149,770. At the inception of the Asher Notes, the Company determined the aggregate fair value of $566,294 of the embedded derivatives. 2015 Notes During the year ended December 31, 2015, the Company entered into Securities Purchase Agreements with Asher Enterprises, Inc. (“Asher”) or affiliates, for the sale of 8% convertible notes in aggregate principal amount of $180,000 (the “Asher Notes”). The Company incurred legal fees in the amount of $15,000 which were deducted from the proceeds of the notes. The Asher Notes bear interest at the rate of 8% per annum. As of the year ended December 31, 2015, all interest and principal must be repaid nine months from the issuance date, with the last note being due February 6, 2016. The Asher Notes are convertible into shares of common stock, at Asher’s option, at a 45% discount to the average of the three lowest closing bid prices of the shares of common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Asher Notes. (see Note 10) These embedded derivatives included certain conversion features and a reset provision. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Asher Notes and to fair value as of each subsequent reporting date, which at December 31, 2015 was $-0- (all Notes converted). At the inception of the Asher Notes, the Company determined the aggregate fair value of $211,575 of the embedded derivatives. During the year ended December 31, 2015, $151,000 of notes plus accrued interest that were outstanding at December 31, 2014, and $180,000 of notes plus accrued interest that were issued during 2015, were converted into shares of the Company’s common stock (see Note 11). The remaining aggregate Asher Notes unconverted principle balance as of December 31, 2015 was $-0-. Daniel James Management 2014 Notes During the year ended December 31, 2014, the Company entered into Securities Purchase Agreements with Daniel James Management (“Daniel”) for the sale of 8% to 9.5% convertible notes in aggregate principal amount of $135,000 (the “Daniel Notes”). The Daniel Notes bear interest at the rate of 8% to 9.5% per annum. As of the year ended December 31, 2014, all interest and principal must be repaid one year from the issuance date, with the last note being due November 30, 2015. The Daniel Notes are convertible into common stock, at holder’s option, at a 47% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Daniel Note. These embedded derivatives included certain conversion features and reset provision. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Daniel Notes and to fair value as of each subsequent reporting date which at December 31, 2014 was $95,866. At the inception of the Daniel Notes, the Company determined the aggregate fair value of $236,211 of the embedded derivatives. 2015 Notes During the year ended December 31, 2015, the Company entered into Securities Purchase Agreements with Daniel James Management (“Daniel”) for the sale of 9.5% convertible note in aggregate principal amount of $125,000 (the “Daniel Notes”). The Daniel Notes bear interest at the rate of 9.5% per annum. As of the year ended December 31, 2015, all interest and principal must be repaid one year from the issuance date, with the last note being due October 29, 2016. The Daniel Notes are convertible into common stock, at holder’s option, at a 47% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Daniel Notes. These embedded derivatives included certain conversion features and reset provision. (see Note 9). The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Daniel Notes and to fair value as of each subsequent reporting date which at December 31, 2015 was $120,263. At the inception of the Daniel Notes, the Company determined the aggregate fair value of $238,443 of the embedded derivatives. During the year ended December 31, 2015, $75,000 of notes plus accrued interest that were outstanding at December 31, 2014, and $50,000 of notes plus accrued interest that were issued during 2015, were converted into shares of the Company’s common stock (see Note 11). The remaining aggregate Daniel Notes unconverted principle balance as of December 31, 2015 was $75,000. Fourth Man, LLC 2014 Notes During the year ended December 31, 2014, the Company entered into Securities Purchase Agreements with Fourth Man, LLC. (“Fourth Man”), for the sale of an 8% to 9.5% convertible notes in the aggregate principal amount of $100,000 (the “Note”). The Notes bears interest at the rate of 8% to 9.5% per annum. As of the year ended December 31, 2014, all interest and principal must be repaid one year from the issuance date, with the last note being due August 28, 2015. The Notes are convertible into common stock, at Fourth Man’s option, at a 47% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Fourth Man Notes. These embedded derivatives included certain conversion features and reset provision. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Fourth Man Notes and to fair value as of each subsequent reporting date which at December 31, 2014 was $93,505. At the inception of the Fourth Man Notes, the Company determined the aggregate fair value of $168,501 of the embedded derivatives. 2015 Notes During the year ended December 31, 2015, the Company entered into Securities Purchase Agreements with Fourth Man, LLC. (“Fourth Man”), for the sale of a 9.5% convertible notes in the aggregate principal amount of $150,000 (the “Notes”). The Notes bears interest at the rate of 8% to 9.5% per annum. As of the year ended December 31, 2015, all interest and principal must be repaid one year from the issuance date, with the last note being due December 2, 2016. The Notes are convertible into shares of common stock, at Fourth Man’s option, at a 47% discount to the lowest closing bid price of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Fourth Man Notes. These embedded derivatives included certain conversion features and reset provision. (see Note 10) The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Fourth Man Notes and to fair value as of each subsequent reporting date which at December 31, 2015 was $126,825. At the inception of the Fourth Man Notes, the Company determined the aggregate fair value of $356,225 of the embedded derivatives. During the year ended December 31, 2015, $75,000 of notes plus accrued interest that were outstanding at December 31, 2014, and $72,550 of notes plus accrued interest that were issued during 2015, were converted into shares of the Company’s common stock (see Note 11). The remaining aggregate Fourth Man, LLC Notes unconverted principle balance as of December 31, 2015 was $77,450. Magna Group 2014 Note During the year ended December 31, 2014, the Company entered into a Securities Purchase Agreement with Magna Capital Group (“Magna”) for the sale of a convertible note in aggregate principal amount of $307,500 (the “Magna Note”) and an original interest discount (“OID”) of $102,500. $40,000 of the outstanding principal amount of the Convertible Note (together with any accrued and unpaid interest with respect to such portion of the principal amount) will be automatically extinguished upon the filing of the registration statement, following the closing of the Securities Purchase Agreement. In addition, $62,500 of the outstanding principal amount of the Convertible Note (together with any accrued and unpaid interest with respect to such portion of the principal amount) will be automatically extinguished if (i) the registration statement is declared effective by the SEC on or prior to the earlier of (A) the 120 th The Convertible Note matured on August 7, 2015 and, in addition to the approximately 33.33% original issue discount, accrues interest at the rate of 12% per year. The Convertible Note is convertible at any time, in whole or in part, at Magna’s option into shares of Company common stock at a fixed conversion price of $10.35 per share, subject to adjustment pursuant to the “full ratchet” and standard anti-dilution provisions contained in the Convertible Note. This resulted in an embedded derivatives liability as a result of these anti-dilution provision. This conversion price represents a discount of approximately 45% from the lowest trading price the Company common stock during the five trading days prior to October 7, 2014, the date the Company issued the Convertible Note to Magna. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivative as of the inception date of Magna Note and to fair value as of each subsequent reporting date which at December 31, 2014 was $252,211. At the inception of the Magna Note, the Company determined the aggregate fair value of $472,702 of the embedded derivative. At the dates of debt reductions, as described above, the Company reclassified the fair value of the related derivative liability of $128,624 to additional paid in capital. On August 6, 2015, the Company amended the securities purchase agreement with Magna amending the maturity date of its convertible note payable with Magna from August 7, 2015 to November 7, 2015. This amendment also changes the conversion price of the notes from $10.35 to the lesser of a) $6.00 or b) a 40% discount from the lowest trading price in the five trading days prior to conversion. Due to the reset provisions embedded in the initial convertible note, the Company determined the modification was immaterial. The Company has identified the embedded derivatives related to the Magna Note. These embedded derivatives included certain conversion features and a reset provision. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of the 2014 Magna Notes and to fair value as of each subsequent reporting date which at December 31, 2015 was $-0- (Notes fully converted). 2015 Notes On October 1, 2015, the Company entered into a securities purchase agreement with Magna Equities II, LLC. The purchase agreement provides that Magna shall purchase from the Company on the closing date a senior convertible note with an initial principal amount of $110,000 for a purchase price of $100,000. The Note bears interest at the rate of 12% per annum. All interest and principal must be repaid on August 1, 2016 . The convertible note is convertible at any time, in whole or in part, at Magna’s option into shares of the Company’s common stock at a the lower of i) 60% discount to the lowest trading price of the common stock during the 5 trading day period prior to conversion or ii) $0.70 per share. On December 3, 2015, the Company entered into a convertible promissory note with Magna Equities II, LLC. The note provides that Magna shall pay on the Company’s behalf certain accrued legal fees of $15,000. The December 3, 2015 convertible note bears interest at the rate of 12% per annum. All interest and principal must be repaid on August 1, 2016 . The convertible note is convertible at any time, in whole or in part, at Magna’s option into shares of the Company’s common stock at the lower of 60% of the lowest sale price of the Company’s common stock during five trading days preceding conversion date or $0.70 per share (subject to adjustment). The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Magna Notes and to fair value as of each subsequent reporting date which at December 31, 2015 was $164,600. At the inception of the Magna Note, the Company determined the aggregate fair value of $291,136 of the embedded derivatives. During the year ended December 31, 2015, $205,000 of note that were outstanding at December 31, 2014, plus accrued interest, were converted into shares of the Company’s common stock (see Note 11). The remaining Magna notes principle balance as of December 31, 2015 was $125,000. On December 3, 2015, the Company entered into a securities purchase agreement with Magna Equities II, LLC. The purchase agreement provides that Magna shall purchase from the Company a senior convertible note with an initial principal amount of $262,500, subject to filing and becoming effective PowerUp Lending Group, Ltd In July 2015, the Company entered into two revenue based factoring agreements and received an aggregate of $180,000 (less origination fees of $3,590) in exchange for $243,000 of future receipts relating to monies collected from customers or other third party payors. Under the terms of the agreements, the Company is required to make daily payments equal to the greater of $1,464 or 20% of the Company’s daily cash or monetary sales receipts over the term of the agreements (ranging from 126 to 189 business days). The Company has recorded a debt discount which is being amortized to interest expense over the term of the agreements. On December 17, 2015, the Company entered into a revenue based factoring agreement and received an aggregate of $150,000 (less origination fees of $4,500) in exchange for $202,500 of future receipts relating to monies collected from customers or other third party payors. Under the terms of the agreements, the Company is required to make daily payments equal to $1,378 for 147 business days. The Company received net proceeds of $53,642 along with cancellation of the previous two revenue based factoring agreements described above. In connection with the cancellation of the July 2015 revenue based factoring agreements, the Company incurred a loss in settlement of debt of $8,679. The remaining principle balance of the PowerUp Lending Group notes payable at December 31, 2015 is $194,235 At December 31, 2015, the Company has recorded interest expense in the amount of $44,226 under the terms of the agreements. The remaining unamortized debt discount at December 31, 2015 is $51,164. Equipment finance lease On November 19, 2015, the Company entered into a financing lease for office equipment with an imputed interest of 7.75% payable at $116 per month over 48 months, secured by the leased equipment. The remaining principle balance of the equipment finance lease as of December 31, 2015 was $4,777. Promissory note At December 31, 2014, a related party to one of the Company’s former officers provided notes in aggregate of $1,500,000. As of December 31, 2014, these notes were not considered as related party. The notes range from 4.75% to 8% per annum and are due upon payoff of the Northstar note payable described in Note 8. On June 1, 2015, the Company issued an amended and restated promissory note of $1,697,762 in settlement of the $1,500,000 outstanding subordinated debt, related accrued interest of $373,469 and accumulated and unpaid guarantor fees of $624,737 (See Note 5). The note is unsecured and non-interest bearing with four semi-annual payments of $75,000 beginning on December 31, 2015 with the remaining unpaid balance due June 1, 2020. The Company imputed an interest rate of 5% and discounted the promissory note accordingly. The imputed debt discount of $368,615 is amortized to interest expense using the effective interest method. For the year ended December 31, 2015, the Company amortized $49,537 of debt discounts to current period operations as interest expense. The unamortized debt discount at December 31, 2015 is $319,385. In connection with the settlement, the Company recorded a gain on settlement of debt of $1,169,058. Summary: The Company has identified the embedded derivatives related to the Asher, Daniel, Fourth Man LLC and Magna notes. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of these notes and to fair value as of each subsequent reporting date which at December 31, 2015 was $411,718. The fair value of the embedded derivatives at issuance of the Asher, Daniel, Fourth Man and Magna Notes, was determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%, (2) expected volatility of 111.98% to 175.1%, (3) weighted average risk-free interest rate of 0.17% to 0.57%, (4) expected lives of 0.75 to 1.00 years, and (5) estimated fair value of the Company’s common stock from $1.10 to $12.70 per share. The initial fair value of the embedded debt derivative of $1,097,379 was allocated as a debt discount up to the proceeds of the notes ($568,464) with the remainder ($528,915) charged to current period operations as interest expense. For the year ended December 31, 2015, the Company amortized an aggregate of $768,241 of debt discounts to current period operations as interest expense.

NOTE 9 - RELATED PARTY TRANSACT

NOTE 9 - RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	NOTE 9 — RELATED PARTY TRANSACTIONS Advances As of December 31, 2015 and 2014, the Company officers and directors have provided advances in the aggregate of $106,505 and $98,759 respectively, for working capital purposes. The advances are unsecured, due on demand and non-interest bearing. During the year ended December 31, 2014, the Company issued an aggregate of 10,232 shares of common stock in settlement of $298,759 of related party advances and outstanding accounts payable. On November 4, 2015, the Company issued 3,411 shares of common stock in settlement of $5,860 of related party advances. Notes payable-related party Northstar Biotechnology Group, LLC On February 29, 2012, a note issued to BlueCrest Master Fund Limited was assigned to Northstar Biotechnology Group, LLC (“Northstar”), owned partly by certain directors and existing shareholders of the Company, including Dr. William P. Murphy Jr., Dr. Samuel Ahn and Charles Hart. At the date of the assignment, the principal amount of the BlueCrest note was $544,267. On March 30, 2012, the Company and Northstar agreed to extend until May 1, 2012 the initial payment date for any and all required monthly under the Note, such that the first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012, and to waive any and all defaults and/or events of default under the Note with respect to such payments. The Company did not make the required payment, and as a result, was in default of the revised agreement The Company renegotiated the terms of the Note and Northstar agreed to suspend the requirement of principal payments by the Company and allow payment of interest-only in common stock. On September 21, 2012, the Company issued 5,000 common stock purchase warrants to Northstar that was treated as additional interest expense upon issuance. On October 1, 2012, the Company and Northstar entered into a limited waiver and forbearance agreement providing a recapitalized new note balance comprised of all sums due Northstar with a maturity date extended perpetually. The Company agreed to issue 5,000,000 shares of Series A Convertible Preferred Stock and 10,000 of common stock in exchange for $210,000 as payment towards outstanding debt, default interest, penalties, professional fees outstanding and due Northstar. In addition, the Company executed a security agreement granting Northstar a lien on all patents, patent applications, trademarks, service marks, copyrights and intellectual property rights of any nature, as well as the results of all clinical trials, know-how for preparing Myoblasts, old and new clinical data, existing approved trials, all right and title to Myoblasts, clinical trial protocols and other property rights. In addition, the Company granted Northstar a perpetual license on products as described for resale, relicensing and commercialization outside the United States. In connection with the granted license, Northstar shall pay the Company a royalty of up to 8% on revenues generated. Effective October 1, 2012, the effective interest rate was 12.85% per annum. The parties agreed, as of February 28, 2013, to reduce the interest rate to 7% per annum. In connection with the consideration paid, Northstar waived, from the effective date through the earlier of termination or expiration of the agreement, satisfaction of the obligations as described in the forbearance agreement. In 2012, 5,000,000 shares of Series A Convertible Preferred Stock were approved to be issued, which was subsequently increased to 20,000,000 shares of preferred stock as Series A Convertible Preferred Stock. In addition, the Company is obligated to issue additional preferred stock equal in lieu of payment of cash of accrued and unpaid interest on each six month anniversary of the effective date (October 1, 2012). In lieu of the initial two payments in preferred stock, the parties have determined to modify the voting rights of the Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stock holders to 25 votes per share on matters to be voted on by the common stock holders and all prior and subsequent payments of interest will be in common stock. The Company is required to issue additional shares of its common stock (as amended), in lieu of cash, each six month anniversary of the effective date for any accrued and unpaid interest. As described above, during the year ended December 31, 2013, the Company issued the 5,000,000 shares of Series A Convertible Preferred Stock and the 10,000 of common stock described above in exchange for the $210,000 as payment towards outstanding principle of the debt. In addition, the Company issued 15,000,000 shares of Series A Convertible Preferred Stock as a penalty in settlement of the terms of the forbearance agreement. The fair value of the Preferred Stock of $274,050 was included in interest expense for the year ended December 31, 2013. On September 30, 2013, the Company issued 8,772 shares of its common stock as payment of $100,000 towards cash advances. On December 24, 2013, the Company issued 3,916 shares of its common stock as payment of accrued interest through June 30, 2013 of $85,447. On April 2, 2014, the Company issued 275 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,635 due April 1, 2014 per the forbearance agreement. On September 17, 2014, limited waiver and forbearance agreement entered into on October 1, 2012 to provide that the perpetual license on products as described for resale, relicensing and commercialization outside the United States was amended as such to condition upon NorthStar providing certain financing, which financing the Company, in its sole discretion, could decline and retain the license. On October 3, 2014, the Company issued 515 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,705 due October 1, 2014 per the forbearance agreement. On April 3, 2015, the Company issued 1,363 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,635 due April 1, 2015 per the forbearance agreement. On October 2, 2015, the Company issued 4,156 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,705 due October 1, 2015 per the forbearance agreement. On October 7, 2015, the Company issued 34,522 shares of its common stock in settlement of $100,000 principal payment towards the outstanding debt. As of December 31, 2015 and 2014, the principle of this note was $262,000 and $362,000, respectively. U.S. Stem Cell Clinic, LLC On November 6, 2015, the Company issued a 4% promissory note to U.S. Stem Cell Clinic, Inc for $30,000 due November 3, 2017 (See Note 3). Officer and Director Notes 2015 2014 Notes payable, Dr. Murphy $ - $ 465,240 Note payable, Beverly Murphy 50,000 50,000 Note payable, Mr. Tomas 252,250 331,354 Note payable, Mr. Tomas 375,000 375,000 Note payable, Mr. Tomas 500,000 500,000 Note payable, Ms. Comella 287,772 299,465 Total $ 1,465,022 $ 2,021,059 Notes payable, Dr. Murphy At December 31, 2014, the Company has outstanding notes payable to Dr. Murphy with interest at 8% per annum due at maturity in aggregate $465,240. Of the outstanding balance, certain subordinated notes totaling $100,000 and $140,000 were previously due on November 30, 2012 and June 4, 2011 respectively, and are unsecured. The Company is not obligated to make payment until Northstar (or successor) Loan is paid off. On June 20, 2014, the Company issued 10,333 shares of its common stock in settlement of $298,386 of related party note payable, $2,000 advances and accrued interest of $112,954. On November 4, 2015, the Company issued 270,800 shares of common stock in settlement of $465,200 of outstanding notes payable to Dr. Murphy. Note payable, Ms. Murphy At December 31, 2015 and 2014, the Company has outstanding note payable of $50,000 due to Beverly Murphy with interest at 7% per annum due at maturity at October 15, 2015. Note payable, Dr. Ahn At December 31, 2013, the Company has outstanding note payable for $125,000 to Dr. Ahn with interest at 8% per annum due at maturity. On June 20, 2014, the Company issued 4,046 shares of its common stock in settlement of $125,000 of related party note payable and accrued interest of $36,832. There were no amounts outstanding as of December 31, 2015 and 2014. Notes payable, Mr. Tomas In 2013, the Company issued a promissory note payable for previous advances and accrued compensation. The promissory note bears interest of 5% per annum and due on demand. During the year ended December 31, 2015 and 2014, the Company paid off $79,104 and $186,779 of the outstanding promissory note, respectively. The principle outstanding balance of this note as of December 31, 2015 is $252,250. On August 1, 2013, the Company issued a $375,000 promissory note due on demand in settlement of accrued compensation. The promissory note bears interest of 5% per annum and is due on demand. The principle outstanding balance of this note as of December 31, 2015 is $375,000. On July 1, 2014, the Company issued a $500,000 promissory note in settlement of accrued compensation. The promissory note bears interest of 5% per annum and was due on January 1, 2015. The principle outstanding balance of this note as of December 31, 2015 is $500,000. Notes payable, Ms. Comella On August 1, 2013, the Company issued a $125,000 promissory notes due on demand in settlement of accrued compensation. The promissory note bear interest of 5% per annum and due on demand. During the year ended December 31, 2014 and 2013, the Company paid off $97,718 and $27,282 of the outstanding promissory note. The principle outstanding balance of these notes as of December 31, 2015 is $-0-. On July 1, 2014, the Company issued a $300,000 promissory note in settlement of accrued compensation. The promissory note bears interest of 5% per annum and due on January 1, 2015. During the years ended December 31, 2015 and 2014, the Company paid off $11,693 and $535 of the outstanding promissory note, respectively. The principle outstanding balance of this note as of December 31, 2015 is $287,772. Transactions with Pavillion During the years ended December 31, 2015 and 2014, the Company purchased $242,271 and $302,899 lab kits from Pavillion, Inc., respectively, a related party whose owner is related to an officer of the Company. As of December 31, 2015 and 2014, the Company had $74,793 and $23,862, respectively, in accounts payable owed to Pavillion.

NOTE 10 - DERIVATIVE LIABILITIE

NOTE 10 - DERIVATIVE LIABILITIES	12 Months Ended
	Dec. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities Disclosure [Text Block]	NOTE 10 — DERIVATIVE LIABILITIES Reset warrants On October 1, 2012, in connection with the forbearance agreement with Northstar as discussed in Note 9 above, the Company issued an aggregate of 15,000 common stock purchase warrants to purchase the Company’s common stock with an exercise price of $14.00 per share for ten years with anti-dilutive (reset) provisions. The Company has identified embedded derivatives related to the issued warrants. These embedded derivatives included certain and anti-dilutive (reset) provisions. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date and to fair value as of each subsequent reporting date. At December 31, 2015, the fair value of the reset provision related to the embedded derivative liability of $12,209 was determined using the Binomial Option Pricing model with the following assumptions: dividend yield: 0%; volatility: 178.53%; risk free rate: 2.09%; and expected life: 6.75 years. The Company recorded a gain on change in derivative liabilities of $137,710 during the year ended December 31, 2015. Convertible notes In 2014 and 2015, the Company issued convertible notes (see Note 8). These notes are convertible into common stock, at holders’ option, at a discount to the market price of the Company’s common stock. The Company has identified the embedded derivatives related to these notes relating to certain anti-dilutive (reset) provisions. These embedded derivatives included certain conversion features. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of these notes and to fair value as of each subsequent reporting date. The fair value of the embedded derivatives at December 31, 2015, in the amount of $411,718, was determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 178.53%, (3) weighted average risk-free interest rate of 0.49 to 0.65%, (4) expected lives of 0.42 to 0.92 years, and (5) estimated fair value of the Company’s common stock of $0.875 per share. The Company recorded a loss on change in derivative liabilities of $122,615 during the year ended December 31, 2015. Based upon ASC 840-15-25 (EITF Issue 00-19, paragraph 11) the Company has adopted a sequencing approach regarding the application of ASC 815-40 to its outstanding convertible notes. Pursuant to the sequencing approach, the Company evaluates its contracts based upon earliest issuance date.

NOTE 11 - STOCKHOLDERS' EQUITY

NOTE 11 - STOCKHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 11 — STOCKHOLDERS’ EQUITY Preferred stock On August 17, 2012, the Board of Directors designated 5,000,000 shares of preferred stock as Series A Convertible Preferred Stock which was increased to 20,000,000 shares of preferred stock as Series A Convertible Preferred Stock (currently held by Northstar Biotechnology Group, LLC). Each share of preferred stock is convertible into equal number of common shares at the option of the holder; entitled to 20 votes on all matters presented to be voted by the holders of common stock; upon event of liquidation, entitled to amount equal to stated value plus any accrued and unpaid dividends or other fees before distribution to junior securities. In lieu of the initial two payments due to Northstar on April 1, 2013 and October 1, 2013, the parties have determined to modify the voting rights of the Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stock holders to 25 votes per share on matters to be voted on by the common stock holders (see Note 9). During the year ended December 31, 2013, the Company issued an aggregate of 20,000,000 shares of Series A Convertible Preferred Stock for principle payment and settlement of forbearance (see note 9 above). Common stock Effective May 19, 2014, the Company amended its articles of incorporation to increase the authorized shares of capital stock of the Company from nine hundred and fifty million (950,000,000) shares of common stock and twenty million (20,000,000) shares of preferred stock, both $.001 par value respectively, to two billion (2,000,000,000) shares of shares of common stock and twenty million (20,000,000) shares of preferred stock, both $.001 par value respectively. On October 12, 2015, the Company filed an amendment to its Articles of Incorporation and effected a 1-for-1,000 reverse stock split of its issued and outstanding shares of common stock, $0.001 par value, effective November 19, 2015. The Financial Industry Regulatory Authority (“FINRA”) declared the ex-dividend date for the dividend date as November 4, 2015. All per share amounts and number of shares in the condensed financial statements and related notes have been retroactively restated to reflect the reverse stock split as if it had occurred on the first day of the first period presented resulting in the transfer of $580,852 from common stock to additional paid in capital at December 31, 2014. During the year ended December 31, 2015, the Company issued an aggregate of 62,425 shares of its common stock in the amount of $211,546 for the settlement of outstanding accounts payable and accrued expenses. In connection with the issuance of the shares the Company recognized a gain on settlement of accounts payable and accrued expenses in the amount of $144,669 (see Note 5). During the year ended December 31, 2015, the Company issued 6,650 shares of common stock in settlement of litigation. In connection with the issuances, the Company recognized a loss in the amount of $59,850, which is included in the marketing, general and administration expense in the Statement of Operations (see Note 13). On April 3, 2015, the Company issued 1,363 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,635 due April 1, 2015 per the forbearance agreement on Northstar note (See Note 9). On October 2, 2015, the Company issued 4,156 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,705 due October 1, 2015 per the forbearance agreement on Northstar note (See Note 9). During the year ended December 31, 2015, the Company issued an aggregate of 763,434 shares of its common stock for the conversion of $949,017 of notes payable and related accrued interest. Upon conversion of the notes, the Company recorded an adjustment to the derivative liability in the amount of $1,399,628 (see Note 13). On November 4, 2015, the Company issued 270,800 shares of common stock in settlement of $465,200 of outstanding notes payable to Dr. Murphy. On November 4, 2015, the Company issued 3,411 shares of common stock in settlement of $5,860 of related party advances. During the year ended December 31, 2015, the Company purchased 85,211 shares of the Company’s common stock in the open market at an average cost of $2.61 per share. During the year ended December 31, 2015, the Company issued an aggregate of 87,812 shares of common stock in exchange for $521,538 under the stock purchase agreement with Magna Equities II, LLC (see Note 7), and issued an aggregate of 7,852 shares of common stock in exchange for $61,270. In connection with the stock sale, the Company issued an aggregate of 1,444 warrants to purchase the Company’s common stock (see Note 12). During the year ended December 31, 2015, the Company issued an aggregate of 24,353 shares of its common stock in settlement of accumulative outstanding amounts due to Guarantors of the Company of $961,125. In connection with the issuance, the Company incurred a $791,024 gain in settlement of debt. During the year ended December 31, 2014, the Company issued 42,067 shares of common stock for proceeds of $479,625. During the year ended December 31, 2014, the Company issued an aggregate of 48,585 shares of its common stock in settlement of outstanding accounts payable and accrued expenses. In connection with the issuance, the Company incurred $120,656 gain in settlement of debt. During the year ended December 31, 2014, the Company issued an aggregate of 83,236 shares of its common stock for the conversion of $1,974,917 of notes payable and related accrued interest. In connection with the issuance, the Company incurred $255,890 gain in settlement of debt. During the year ended December 31, 2014, the Company issued an aggregate of 3,840 shares of its common stock for services provided to the Company valued at $183,991. During the year ended December 31, 2014, the Company issued an aggregate of 11,918 shares of its common stock in connection with the exercise of warrants. During the year ended December 31, 2014 the Company issued Magna Group 12,000 shares of its common stock as a commitment fee for entering into the Purchase Agreement (See Note 7).

NOTE 12 - STOCK OPTIONS AND WAR

NOTE 12 - STOCK OPTIONS AND WARRANTS	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	NOTE 12 — STOCK OPTIONS AND WARRANTS Stock Options In December 1999, the Board of Directors and shareholders adopted the 1999 Officers and Employees Stock Option Plan, or the Employee Plan, and the 1999 Directors and Consultants Stock Option Plan, or the Director Plan. The Employee Plan and the Director Plan are collectively referred to herein as the Plans. The Plans are administered by the Board of Directors and the Compensation Committee. The objectives of the Plans include attracting and retaining key personnel by encouraging stock ownership in the Company by such persons. In February 2010, the Directors & Consultants Plan was amended to extend the termination date of the Plan to December 1, 2011. On April 1, 2013, the Board of Directors approved, subject to shareholder approval, the establishment of the Bioheart 2013 Omnibus Equity Compensation Plan, or the “2013 Omnibus Plan”. The 2013 Omnibus Plan reserves up to fifty thousand shares of common stock for issuance. On August 4, 2014, the Board of Directors approved to set the reserve to one hundred thousand shares of common stock for issuance and to close the 1999 Officers and Employees Stock Option Plan. On February 2, 2015, at the annual meeting of shareholders, the majority of shareholders approved the 2013 Omnibus Equity Compensation Plan. On November 2, 2015, the Board of Directors approved the increase of the reserve under the 2013 Omnibus Plan to five hundred million shares of common stock for issuance. A summary of options at December 31, 2015 activity during the years ended December 31, 2015 and 2014 is presented below: Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Options outstanding at January 1, 2014 23,921 $ 150.00 9.0 Granted 43,148 $ 23.00 10.0 Exercised — $ Forfeited/Expired (136 ) $ 5,200.00 Options outstanding at December 31, 2014 66,933 $ 56.00 8.9 Granted 489,116 $ 1.98 10.0 Exercised — Forfeited/Expired (229 ) $ 5,103.28 Options outstanding at December 31, 2015 555,820 $ 6.43 9.6 Options exercisable at December 31, 2015 511,660 $ 5.60 9.7 Available for grant at December 31, 2015 7,383,070 The following information applies to options outstanding and exercisable at December 31, 2015: Options Outstanding Options Exercisable Shares Weighted- Average Remaining Contractual Term Weighted- Average Exercise Price Shares Weighted- Average Exercise Price $ 0.00 – $20.00 534,706 9.7 $ 3.32 501,682 $ 2.72 $ 20.01 – $30.00 19,849 8.5 $ 26.96 8,713 $ 26.94 $ 30.01 – $100.00 300 5.7 $ 70.00 300 $ 70.00 $ >100.00 965 4.0 $ 1,288.36 965 $ 1,288.36 555,820 9.6 $ 6.43 511,660 $ 5.60 On February 24, 2014, the Company issued an aggregate 15,000 options to purchase the Company’s common stock at $19.00 per share to officers, vesting at 25% immediately and the remainder over approximately 42 months, exercisable over 10 years. The aggregate fair value of $282,597, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 163.63% and Risk free rate: 2.75%. On February 24, 2014, the Company issued an aggregate 4,800 options to purchase the Company’s common stock at $19.00 per share to officers, vesting immediately and exercisable over 10 years. The aggregate fair value of $90,431, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 163.63% and Risk free rate: 2.75%. On May 12, 2014, the Company issued an aggregate 4,848 options to purchase the Company’s common stock at $27.20 per share to officers and employees, vesting over four years at anniversary and exercisable over 10 years. The aggregate fair value of $130,135, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 161.36% and Risk free rate: 2.66%. On August 1, 2014, the Company issued an aggregate 15,000 options to purchase the Company’s common stock at $26.94 per share to officers and employees, vesting at 25% immediately and 75% over three years at anniversary and exercisable over 10 years. The aggregate fair value of $391,798, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 168.62% and Risk free rate: 2.52%. On November 3, 2014, the Company issued an aggregate 700 options to purchase the Company’s common stock at $19.32 per share to officers and employees, vesting at 25% each year over four years at anniversary and exercisable over 10 years. The aggregate fair value of $12,739, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 152.87% and Risk free rate: 2.36%. On November 3, 2014, the Company issued an aggregate 2,800 options to purchase the Company’s common stock at $19.32 per share to board of directors, vesting immediately and exercisable over 10 years. The aggregate fair value of $54,957, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 152.87% and Risk free rate: 2.36%. On February 2, 2015, the Company issued an aggregate 7,000 options to purchase the Company’s common stock at $11.16 per share to members of the Board of Directors, vesting immediately and exercisable over 10 years. The aggregate fair value of $121,735, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 142.65% and Risk free rate: 1.68%. On August 24, 2015, the Company issued 100 options to purchase the Company’s common stock at $5.31 per share to a consultant, vesting immediately and exercisable over 4 years. The aggregate fair value of $347, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 129.01% and Risk free rate: 1.39%. On November 2, 2015, the Company issued an aggregate of 467,016 options to purchase the Company’s common stock at $1.713 per share to two officers, vesting immediately and exercisable over 10 years. The aggregate fair value of $738,405 determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 160.66% and Risk free rate: 1.57%. On November 2, 2015, the Company issued an aggregate of 15,000 options to purchase the Company’s common stock at $6.24 per share to two officers, vesting over four years on each anniversary and exercisable over 10 years. The aggregate fair value of $23,512, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 160.66% and Risk free rate: 1.93%. The fair value of all options vesting during the year ended December 31, 2015 and 2014 of $1,156,435 and $537,606, respectively, was charged to current period operations. As of December 31, 2015, the Company had approximately $473,898 of total unrecognized compensation cost related to non-vested awards granted under the Plan, which the Company expects to recognize over a weighted average period of 1.0 year. Warrants A summary of common stock purchase warrants at December 31, 2015 and activity during the years ended December 31, 2015 and 2014 is presented below: Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Outstanding at January 1, 2014 118,134 $ 220.00 6.3 Issued 57,582 $ 20.00 8.2 Exercised (11,918 ) $ 10.00 Expired (13,178 ) $ 80.00 Outstanding at December 31, 2014 150,620 $ 170.00 6.6 Issued 2,072 $ 19.98 8.18 Exercised - $ Expired (13,325 ) $ 24.00 Outstanding at December 31, 2015 139,367 $ 182.26 6.3 Exercisable at December 31, 2015 133,822 $ 99.98 6.3 The following information applies to common stock purchase warrants outstanding and exercisable at December 31, 2015: Warrants Outstanding Warrants Exercisable Shares Weighted- Average Remaining Contractual Term Weighted- Average Exercise Price Shares Weighted- Average Exercise Price $ 0.01 – $20.00 94,108 6.8 $ 15.54 94,108 $ 15.54 $ 20.01 – $30.00 29,743 6.1 $ 24.52 27,743 $ 24.72 $ 30.01 – $40.00 628 1.6 $ 40.00 628 $ 40.00 $ 40.01 - $50.00 6,253 3.1 $ 48.36 4,253 $ 48.49 $ 50.01 – $60.00 543 1.9 $ 60.00 543 $ 60.00 $ >60.00 8,092 4.2 $ 2,823.67 6,547 $ 1,675.28 139,367 6.3 $ 182.26 133,822 $ 99.98 In conjunction with the authorized issuance of common stock, the Company issued 41,582 common stock purchase warrants during the year ended December 31, 2014. During the year ended December 31, 2014, the Company issued an aggregate of 8,000 warrants in connection with a revenue share venture agreement dated March 10, 2014. The warrants are exercisable at $21.70 for four years vesting from June 8, 2014 through March 10, 2016 (term of agreement). During the year ended December 31, 2014, the Company charged $103,238 to current period operations. During the year ended December 31, 2014, the Company issued an aggregate of 4,000 warrants in connection with use of certain intellectual property. The warrants are exercisable at $48.10 for four years vesting from July 6, 2014 through April 6, 2017. During the year ended December 31, 2014, the Company charged $32,878 to current period operations for the vesting portion. During the year ended December 31, 2014, the Company issued an aggregate of 4,000 warrants in connection with the termination of a revenue share agreement. The warrants are exercisable at $15.70 for four years vesting May 27, 2015. During the year ended December 31, 2014, the Company charged $54,146 to current period operations. On November 3, 2014, the Company extended an aggregate of 13,064 expiring warrants previously issued to the Company’s board of directors for additional three years. The aggregate change in fair value of $148,517, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 152.87% and Risk free rate: 0.96% was charged to current period operations. In conjunction with the authorized issuance of common stock, the Company issued 1,444 common stock purchase warrants during the year ended December 31, 2015. The warrants are exercisable at an exercise price of approximately $11.27 per share for ten years. During the year ended December 31, 2015, the Company issued 628 warrants in connection with the settlement of debt. The warrants are exercisable at $40.00 for three years. The fair value of $14,886, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 164.06% and Risk free rate: 0.87%. In connection with the settlement, the Company recorded a gain of $10,221 in settlement of debt to current period operations.

NOTE 13 - COMMITMENTS AND CONTI

NOTE 13 - COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 13 — COMMITMENTS AND CONTINGENCIES Leases The Company entered into several operating lease agreements for facilities and equipment. Terms of certain lease arrangements include renewal options, escalation clauses, payment of executory costs such as real estate taxes, insurance and common area maintenance. The landlord has filed a security interest against the assets of the Company. In July 2013, the Company amended its facility lease to extend the term of the lease until July 31, 2016. Approximate annual future minimum lease obligations under non-cancelable operating lease agreements as of December 31, 2015 are as follows: Year ending December 31, 2016 $ 43,830 Rent expense was $131,257 and $128,136 for the years ended December 31, 2015 and 2014, respectively. Revenue Share Agreement On March 10, 2014, the Company entered into a revenue sharing agreement (the Agreement) with Global Stem Cells, Group, LLC and its subsidiaries whereby both parties will participate in marketing for obtaining patients and provide physician training for stem cell treatments under the names of “Regenestem” and “Stem Cell Training,” respectively. In addition, each party will be responsible for selling equipment and kit to existing and previous customers. Profits are divided on a fifty/fifty basis with distribution within 10 days of the accounting for patients and physician training and 30 day with sales of equipment and kits. In November 2014, the Company terminated the Agreement. In consideration of Global Stem Cell Group, LLC’s participation, the Company issued an aggregate of 8,000 warrants to purchase the Company’s common stock for four years at $21.70 per share with 2,000 warrants vesting 90 days from the effective date, 2,000 vesting on each anniversary date for three years. At termination of the revenue share agreement, the Company issued an aggregate of 4,000 warrants to purchase the Company’s common stock. During the year ended December 31, 2014, the Company charged $54,146 to current period operations. Because of the termination of the agreement during 2014, all services were considered final and rendered and the fair value of all 12,000 warrants issued under this agreement were recognized during 2014. William Beaumont Hospital In June 2000, the Company entered into an agreement with William Beaumont Hospital, or WBH, pursuant to which WBH granted to the Company worldwide, exclusive, non-sublicenseable license to two U.S. method patents covering the inducement of human adult myocardial cell proliferation in vitro, or the WBH IP. The term of the agreement is for the life of the patents, which expire in 2015. The Company did not use this license in any of our technologies. The Company had not made any payments to WBH other than the initial payment to acquire the license. The Company has received confirmation from WBH that it has no obligation under the patent license agreement and WBH agreed to terminate the patent license agreement. (See Note 5) Accordingly, the Company has recognized approximately $2,122,130 in settlement of debt which represents the accumulative accrual and related interest from past years under the 2000 patent license agreement during 2014. Employment agreements On July 28, 2014, the Company’s Board of Directors approved the 2014/2015 salary for Mike Tomas, Chief Executive Officer, at $525,000 per year, beginning July 1, 2014 with an incentive bonus ranging from $150,000 to $500,000. In addition, the Board of Directors will grant Mr. Tomas options to be determined on or before June 30, 2015. The Company’s Board of Directors approved a bonus of $500,000 and options to acquire 10,000 shares of the Company’s common stock for ten years with four year vesting and a cashless exercise provision at an exercise price equal to the five day average closing price of the Company’s common stock as of August 1, 2014. The cash bonus may be paid in the form a six month promissory note. On November 2, 2015, the Company granted Mr. Tomas - 291,885 options to acquire the Company’s stock with an exercise price of $1.713 per share, vesting immediately and expiring ten years from the date of issuance. On July 28, 2014, the Company’s Board of Directors approved the 2014/2015 salary for Kristin Comella, Chief Scientific Officer, at $250,000 per year, beginning July 1, 2014 with an incentive bonus ranging from $100,000 to $300,000. In addition, the Board of Directors will grant Ms. Comella options to be determined on or before June 30, 2015. The Company’s Board of Directors approved a bonus of $300,000 and options to acquire 5,000 shares of the Company’s common stock for ten years with four year vesting and a cashless exercise provision at an exercise price equal to the five day average closing price of the Company’s common stock as of August 1, 2014. The cash bonus may be paid in the form a six month promissory note. On November 2, 2015, the Company granted Ms. Comella 175,131 options to acquire the Company’s stock with an exercise price of $1.713 per share, vesting immediately and expiring ten years from the date of issuance Litigation On March 19 2015, the Company settled a prospective dispute with a third party over the use of proprietary information through the issuance of 6,650 shares of common stock. (See Note 11) On November 10, 2014, the Company was served with a lawsuit by an alleged assignee and a guarantor to a Loan Guarantee, Payment and Security Agreement. These parties claim breach of that Agreement and damages of approximately $2.3 Million plus interest. The assignor and assignee also sued the Company’s directors and two past directors and an affiliate shareholder for breach of fiduciary duty, claiming damages as alleged creditors arising out of these parties’ alleged participation in Northstar Biotech Group, LLC, a secured creditor of the Company. On June 1, 2015, the Company settled the lawsuit. As part of the settlement, the Company recorded a gain of $1,169,058. The Company provided a note to the original guarantor in the amount of $1,697,762, to be paid over a five year period with a 0% interest rate. On September 17, 2015, a product liability lawsuit was filed in Broward County, specifically Patsy Bade v. Bioheart, Inc. US Stem Cell Clinics LLC, Aleiandro Perez, ARNP, and Shareen Greenbaum, M.D., and on November 30, 2015, a product liability lawsuit was filed in Broward County, specifically Elizabeth Noble v. Bioheart, Inc. US Stem Cell Clinics LLC, Aleiandro Perez, ARNP, and Shareen Greenbaum, M.D. Both matters are ongoing and the Company intends to defend the matters rigorously . In the event, if ever, of a settlement or loss, management believes that any loss related to the claims will be covered by their insurance policy and that there is no indication that the insurance company will dispute any claim, if ever required The Company is subject to other legal proceedings that arise in the ordinary course of business. In the opinion of management, as of December 31, 2015, the amount of ultimate liability with respect to such matters, if any, in excess of applicable insurance coverage, is not likely to have a material impact on the Company’s business, financial position, results of operations or liquidity. However, as the outcome of litigation and other claims is difficult to predict significant changes in the estimated exposures could exist.

NOTE 14 - INCOME TAXES

NOTE 14 - INCOME TAXES	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	NOTE 14 — INCOME TAXES The Company follows Accounting Standards Codification subtopic 740, Income Taxes (“ASC 740”) which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases using enacted tax rates in effect for the year in which the differences are expected to reverse. The difference between income tax expense computed by applying the federal statutory corporate tax rate and actual income tax expense is as follows: 2015 2014 Income taxes using U.S. federal statutory rate $ (575,971 ) $ (766,194 ) State income taxes, net of federal benefit (47,571 ) (90,051 ) Return to Provision adjustments 116,025 - Stock Option Expirations - 66,043 Net Operating Loss adjustments - (144,824 ) Nontaxable Gain on Derivative Instrument 8,101 933,477 Change in Valuation Allowance 493,123 1,549 Other 6,293 - $ - $ — At December 31, 2015, the significant components of the deferred tax assets (liabilities) are summarized below: 2015 2014 Deferred tax assets: Stock Based Compensation $ 5,099,422 $ 4,794,777 Net Operating Losses 36,323,004 36,117,831 Other 24,774 41,469 Total deferred tax assets 41,447,200 40,954,077 Deferred tax liabilities: - — Total deferred tax liabilities - — Valuation allowance 41,447,200 40,954,077 Net deferred tax assets $ - $ — As of December 31, 2015 and December 31, 2014, the Company had U.S. federal net operating loss carryforwards of approximately $96.5 million and $95.8 million, respectively, which expire at various dates from 2020 through 2035. These net operating loss carryforwards may be used to offset future taxable income and thereby reduce the Company’s U.S. federal income taxes. Section 382 of the Internal Revenue Code of 1986 (the “Code”) imposes an annual limit on the ability of a corporation that undergoes a greater than 50% ownership change to use its net operating loss carry forwards to reduce its tax liability. If in the future the Company issues common stock or additional equity instruments convertible in common shares which result in an ownership change exceeding the 50% limitation threshold imposed by section 382 of the Code, the Company’s net operating loss carryforwards may be significantly limited as to the amount of use in a particular years. In addition, all or a portion of the Company’s net operating loss carryforwards may expire unutilized. As of December 31, 2015 and December 31, 2014, the Company had net operating loss carryforwards for state income tax purposes of approximately $97.5 million and $95.8 million, respectively, which expire at various dates from 2020 through 2035. The Company has provided a full valuation allowance against its net deferred tax assets, since in the opinion of management based upon the earnings history of the Company; it is more likely than not that the benefits of these assets will not be realized. The Company complies with the provisions of FASB ASC 740-10 in accounting for its uncertain tax positions. ASC 740-10 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely that not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. Management has determined that the Company has no significant uncertain tax positions requiring recognition under ASC 740-10. The Company is subject to income tax in the U.S., and certain state jurisdictions. The Company has not been audited by the U.S. Internal Revenue Service, or any states in connection with income taxes. The Company’s tax years generally remain open to examination for all federal and state tax matters until its net operating loss carryforwards are utilized and the applicable statutes of limitation have expired. The federal and state tax authorities can generally reduce a net operating loss (but not create taxable income) for a period outside the statute of limitations in order to determine the correct amount of net operating loss which may be allowed as a deduction against income for a period within the statute of limitations. The Company recognizes interest and penalties related to unrecognized tax benefits, if incurred, as a component of income tax expense.

NOTE 15 - FAIR VALUE MEASUREMEN

NOTE 15 - FAIR VALUE MEASUREMENT	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	NOTE 15 — FAIR VALUE MEASUREMENT The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) on January 1, 2008. ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities. All items required to be recorded or measured on a recurring basis are based upon level 3 inputs. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement. Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the financial statements. The carrying value of the Company’s cash and cash equivalents, accounts receivable, accounts payable, short-term borrowings (including convertible notes payable), and other current assets and liabilities approximate fair value because of their short-term maturity. As of December 31, 2015 or 2014, the Company did not have any items that would be classified as level 1 or 2 disclosures. The Company recognizes its derivative liabilities as level 3 and values its derivatives using the methods discussed in notes 8 and 10. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed in Notes 8 and 10 are that of volatility and market price of the underlying common stock of the Company. As of December 31, 2015 and 2014, the Company did not have any derivative instruments that were designated as hedges. The derivative liability as of December 31, 2015, in the amount of $423,927 has a level 3 classification. The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities as of December 31, 2015: Warrant Liability Debt Derivative Balance, December 31, 2013 $ 146,855 $ 256,956 Total (gains) losses Initial fair value of debt derivative at note issuance — 1,443,708 Initial fair value of derivative relating to reset warrants — — Mark-to-market at December 31, 2014: 3,065 (429,018 ) Transfers out of Level 3 upon increase in authorized shares — — Transfers out of Level 3 upon conversion and settlement of notes — (680,295 ) Balance, December 31, 2014 $ 149,920 $ 591,351 Total (gains) losses Initial fair value of debt derivative at note issuance — 1,097,379 Mark-to-market at December 31, 2015: (137,711 ) 122,616 Transfers out of Level 3 upon conversion or payoff of notes payable — (1,399,628 ) Balance, December 31, 2015 $ 12,209 $ 411,718 Net gain (loss) for the period included in earnings relating to the liabilities held at December 31, 2015 $ 137,711 $ (122,616 ) Fluctuations in the Company’s stock price are a primary driver for the changes in the derivative valuations during each reporting period. The Company’s stock price decreased approximately 22% from December 31, 2014 to December 31, 2015. As the stock price decreases for each of the related derivative instruments, the value to the holder of the instrument generally decreases. Additionally, stock price volatility is one of the significant unobservable inputs used in the fair value measurement of each of the Company’s derivative instruments. Decreases in expected volatility would generally result in a lower fair value measurement. A 10 percent change in pricing inputs and changes in volatilities and correlation factors would result in less than a $70,000 change in our Level 3 fair value.

NOTE 16 - SUBSEQUENT EVENTS

NOTE 16 - SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 16 — SUBSEQUENT EVENTS Seaside Bank loan renewal On January 11, 2016, the Company renewed the loan with Seaside National Bank and Trust extend the maturity date to January 11, 2018, all other terms and conditions remain unchanged. (see Note 8) Office lease renewal On February 4, 2016, the Company extended its facility lease to extend the term of the lease until August 31, 2019 at a monthly base rent of $7,306 plus a pro rata share of landlord’s operating expenses In Connection with the renewal, the Company was required to pay $11,072 security deposit. Approximate annual future minimum lease obligations under this non-cancelable facilities operating lease agreement as of December 31, 2015 are as follows: Year ending December 31, 2016 $ 87,674 2017 87,674 2018 87,674 2019 58,450 Total $ 321,472 Subsequent common stock issuances In January, February and March 2016, the Company issued an aggregate of 625,352 shares of its common stock in settlement of $91,170 notes payable and $2,649 accrued interest; 16,753 shares for services of $13,110 and 14,606 shares in settlement of related party advances. Subsequent financing Magna Equities II, LLC On December 3, 2015, the Company entered into a Securities Purchase Agreement with Magna Equities II, LLC for the sale of a 12% convertible note in the principal amount of $262,500 (the “Note”). The Note was subsequently funded in February 2016 upon effectiveness of the Company’s registration statement (see below). The Note bears interest at the rate of 12% per annum. All interest and principal must be repaid on December 3, 2016. The Note is convertible into common stock, at Magna’s option, at the lower of i) 40% discount to the lowest sales price of the common stock during the 5 trading day period prior to conversion or ii) $0.70. In the event the Company prepays the Note in full, the Company is required to pay off all principal at 140%, interest and any other amounts. On December 12, 2014, the Company filed a Registration Statement on Form S-1 to register 341,718 shares of common issuable upon the conversion of Magna Equity II, LLC convertible notes dated December 3, 2015 (as restated) for $110,000 and December 3, 2015 for $262,500. The latter note was funded in February 2016. The Registration Statement on Form S-1 was declared effective on February 12, 2016 Daniel James Management Inc. On January 7, 2016, the Company entered into a Securities Purchase Agreement with Daniel James Management Inc., for the sale of a 9.5% convertible note in the principal amount of $25,000 (the “Note”). The Note bears interest at the rate of 9.5% per annum. All interest and principal must be repaid on January 7, 2017. The Note is convertible into common stock, at Daniel James Management Inc.’s option, at a 47% discount to the lowest daily closing trading price of the common stock during the 10 trading day period prior to conversion. In the event the Company prepays the Note in full, the Company is required to pay off all principal at 150%, interest and any other amounts. Effective registration statement On February 12, 2016, the Company’s filed registration statement became effective registering common shares issuable upon the conversion of Magna Equity II, LLC convertible notes dated December 3, 2015 (as restated) for $110,000 and December 3, 2015 for $262,500. Related party transactions In February 2016, the Company reimbursed Dr. Murphy, a member of the Company’s board of directors, $100,000 for a previous advance of $50,000 and settlement of accrued interest on related party notes payable.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis and business presentation U.S. Stem Cell, Inc. (the “Company”) was incorporated under the laws of the State of Florida in August, 1999. The Company is in the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Our business includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. To date, the Company has not generated significant sales revenues to cover costs, incurred expenses, and as a result has sustained losses. On October 12, 2015, the Company amended its Articles of Incorporation to change its name from Bioheart, Inc. to U.S. Stem Cell, Inc. and to implement a reverse stock split in the ratio of 1 share for every 1,000 shares of common stock. This amendment was approved and filed of record by the Florida Secretary of State on October 12, 2015, effective on October 19, 2015. FINRA has declared the Company’s 1-for-1,000 reverse stock split market effective as of November 4, 2015. In addition, the ticker symbol was BHRTD for 20 business days from November 4 th
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. At the time of each transaction, management assesses whether the fee associated with the transaction is fixed or determinable and whether or not collection is reasonably assured. The assessment of whether the fee is fixed or determinable is based upon the payment terms of the transaction. Collectability is assessed based on a number of factors, including past transaction history with the client and the creditworthiness of the client. The Company’s primary source of revenue are from the sale of test kits and equipment, training services, patient treatments and laboratory services, and cell banking. Revenues for test kits and equipment sold are not recorded until test kits and equipment are delivered. During 2014, the Company had revenue sharing arrangements for the sale of goods whereby the Company was the primary obligor, set pricing with the customers and bared all associated credit risks with the customers. Sales under revenue share arrangements are recorded as gross sales and any portion shared with third parties under such arrangements are classified as selling expense due to the nature of the marketing activities performed by the third party. All revenue sharing arrangements were terminated in November 2014. Revenues from trainings are recognized when the training occurs. Any cash received as a deposit for trainings are recorded by the company as a liability. Patient treatments and laboratory services revenue are recognized when those services have been completed or satisfied. Revenues for cell banking sales are accounted for as Multiple-Element Arrangements under ASC 605-10 which incorporates Accounting Standards Codification subtopic 605-25, Multiple-Element Arrangements (“ASC 605-25”). ASC 605-25 addresses accounting for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets. Because the Company sells its services separately, on more than a limited basis and at a price within a narrow range, the Company was able to allocate revenue based on vendor-specific objective evidence of fair value (VSOE). At December 31, 2015 and 2014, the Company had deferred revenues of $71,961 and $13,000, respectively.
Use of Estimates, Policy [Policy Text Block]	Estimates The preparation of the financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, revenues and expenses and certain disclosures. The most significant estimates are those used in determination of derivative liabilities and stock compensation. Accordingly, actual results could differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash.
Receivables, Policy [Policy Text Block]	Accounts Receivable Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition.
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Allowance for Doubtful Accounts Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. As of December 31, 2015 and 2014, allowance for doubtful accounts was $-0-.
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost or market with cost being determined on a first-in, first-out (FIFO) basis. The Company writes down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. During 2015 not there were no inventory write-downs.
Equity Method Investments, Policy [Policy Text Block]	Investments The Company has adopted Accounting Standards Codification subtopic 323-10, Investments-Equity Methods and Joint Ventures (“ASC 323-10) which requires the accounting for investments where the Company can exert significant influence, but not control of a joint venture or equity investment. The Company accounted for its 33 percent ownership of U.S. Stem Cell Clinic, LLC utilizing the equity method of accounting.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Long-Lived Assets The Company follows FASB ASC 360-10-15-3, “Impairment or Disposal of Long-lived Assets,” which established a “primary asset” approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. The Company determined that there was no impairment on its long-lived assets during 2015 and 2014.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 15 years.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company has adopted Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statement or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Temporary differences between taxable income reported for financial reporting purposes and income tax purposes consist primarily of derivative liability and stock compensation accounting versus tax differences.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Income The Company does not have any items of comprehensive income in any of the periods presented.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Common Share, basic and diluted The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted income (loss) per share as of December 31, 2015 and 2014 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows: 2015 2014 Convertible notes payable 677,540 901,796 Options to purchase common stock 555,820 66,933 Warrants to purchase common stock 139,367 150,620 Totals 1,372,727 1,119,349
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the statements of operations, as if such amounts were paid in cash. As of December 31, 2015, there were outstanding stock options to purchase 555,820 shares of common stock, 511,660 shares of which were vested. (see Note 12)
Stockholders' Equity, Policy [Policy Text Block]	Treasury Stock The Company use the cost method when it purchases its own common stock as treasury shares and displays treasury stock as a reduction of shareholders’ equity.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Generally, the Company’s cash and cash equivalents in interest-bearing accounts does not exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management. As of December 31, 2015, three customers represented 32%, 18% and 16%, an aggregate of 66% of the Company’s accounts receivable. As of December 31, 2014, two customers represented 38% and 17%, an aggregate of 55%, of the Company’s accounts receivable. The Company’s revenues earned from sale of products and services for the year ended December 31, 2015 did not include any customers representing 10% or more of the Company’s total revenues. For the year ended December 31, 2014, Company’s revenues earned from sale of products and services included 10% of the Company’s total revenues from one customer.
Reliance on Key Personnel and Consultants [Policy Text Block]	Reliance on Key Personnel and Consultants The Company has four full-time employees and one part-time employees. The Company is heavily dependent on the continued active participation of its two current executive officers, one employee and key consultants. The loss of any of the senior management or key consultants could significantly and negatively impact the business until adequate replacements can be identified and put in place.
Research and Development Expense, Policy [Policy Text Block]	Research and Development The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $10,000 and $66,420 for the years ended December 31, 2015 and 2014, respectively.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value.
Derivatives, Policy [Policy Text Block]	Derivative Instrument Liability The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At December 31, 2015 and 2014, the Company did not have any derivative instruments that were designated as hedges. At December 31, 2015 and 2014, the Company had outstanding convertible notes and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions. (See Note 8 and Note 10)
Reclassification, Policy [Policy Text Block]	Reclassification Certain reclassifications have been made to prior periods’ data to conform with the current year’s presentation. These reclassifications had no effect on reported income or losses.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In November 2015, the FASB issued (ASU) 2015-17, Balance Sheet Classification of Deferred Taxes. In January 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU) 2016-01, which amends the guidance in U.S. GAAP on the classification and measurement of financial instruments. Changes to the current guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The new standard is effective for fiscal years and interim periods beginning after December 15, 2017, and upon adoption, an entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company is currently evaluating the impact of adopting this guidance. There were other various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.

NOTE 1 - SIGNIFICANT ACCOUNTI25

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows: 2015 2014 Convertible notes payable 677,540 901,796 Options to purchase common stock 555,820 66,933 Warrants to purchase common stock 139,367 150,620 Totals 1,372,727 1,119,349

NOTE 4 - PROPERTY AND EQUIPME26

NOTE 4 - PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment as of December 31, 2015 and 2014 is summarized as follows: 2015 2014 Laboratory and medical equipment $ 353,253 $ 352,358 Furniture, fixtures and equipment 130,410 125,634 Computer equipment 48,788 47,647 Leasehold improvements 362,046 362,046 894,497 887,685 Less accumulated depreciation and amortization (880,325 ) (874,999 ) $ 14,172 $ 12,686

NOTE 5 - ACCRUED EXPENSES (Tabl

NOTE 5 - ACCRUED EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses consisted of the following as of December 31, 2015 and 2014: 2015 2014 Amounts payable to the Guarantors of the Company’s loan agreement with Bank of America and Seaside Bank, including fees and interest $ 64,199 $ 1,533,217 Interest payable on notes payable 467,664 685,575 Vendor accruals and other 147,244 120,836 Employee commissions, compensation, etc. 47,644 33,987 $ 726,751 $ 2,373,615

NOTE 8 - NOTES PAYABLE (Tables)

NOTE 8 - NOTES PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]	Notes payable were comprised of the following as of December 31, 2015 and 2014: 2015 2014 Seaside Bank note payable. $ 980,000 $ 980,000 Hunton & Williams notes payable 384,972 384,972 Asher notes payable - 151,000 Daniel James Management notes payable 75,000 75,000 Fourth Man, LLC notes payable 77,450 75,000 Magna Group notes payable 125,000 205,000 Power Up Lending Group notes payable 194,235 - Equipment finance lease 4,777 - Total notes payable 1,841,434 1,870,972 Less unamortized debt discount (249,205 ) (339,160 ) Total notes payable net of unamortized debt discount 1,592,229 1,531,812 Less current portion (608,502 ) (1,531,812 ) Long term portion $ 983,727 $ -

NOTE 9 - RELATED PARTY TRANSA29

NOTE 9 - RELATED PARTY TRANSACTIONS (Tables)	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
Schedule of Related Party Transactions [Table Text Block]	2015 2014 Notes payable, Dr. Murphy $ - $ 465,240 Note payable, Beverly Murphy 50,000 50,000 Note payable, Mr. Tomas 252,250 331,354 Note payable, Mr. Tomas 375,000 375,000 Note payable, Mr. Tomas 500,000 500,000 Note payable, Ms. Comella 287,772 299,465 Total $ 1,465,022 $ 2,021,059

NOTE 12 - STOCK OPTIONS AND W30

NOTE 12 - STOCK OPTIONS AND WARRANTS (Tables)	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of options at December 31, 2015 activity during the years ended December 31, 2015 and 2014 is presented below: Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Options outstanding at January 1, 2014 23,921 $ 150.00 9.0 Granted 43,148 $ 23.00 10.0 Exercised — $ Forfeited/Expired (136 ) $ 5,200.00 Options outstanding at December 31, 2014 66,933 $ 56.00 8.9 Granted 489,116 $ 1.98 10.0 Exercised — Forfeited/Expired (229 ) $ 5,103.28 Options outstanding at December 31, 2015 555,820 $ 6.43 9.6 Options exercisable at December 31, 2015 511,660 $ 5.60 9.7 Available for grant at December 31, 2015 7,383,070
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following information applies to options outstanding and exercisable at December 31, 2015: Options Outstanding Options Exercisable Shares Weighted- Average Remaining Contractual Term Weighted- Average Exercise Price Shares Weighted- Average Exercise Price $ 0.00 – $20.00 534,706 9.7 $ 3.32 501,682 $ 2.72 $ 20.01 – $30.00 19,849 8.5 $ 26.96 8,713 $ 26.94 $ 30.01 – $100.00 300 5.7 $ 70.00 300 $ 70.00 $ >100.00 965 4.0 $ 1,288.36 965 $ 1,288.36 555,820 9.6 $ 6.43 511,660 $ 5.60
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	A summary of common stock purchase warrants at December 31, 2015 and activity during the years ended December 31, 2015 and 2014 is presented below: Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Outstanding at January 1, 2014 118,134 $ 220.00 6.3 Issued 57,582 $ 20.00 8.2 Exercised (11,918 ) $ 10.00 Expired (13,178 ) $ 80.00 Outstanding at December 31, 2014 150,620 $ 170.00 6.6 Issued 2,072 $ 19.98 8.18 Exercised - $ Expired (13,325 ) $ 24.00 Outstanding at December 31, 2015 139,367 $ 182.26 6.3 Exercisable at December 31, 2015 133,822 $ 99.98 6.3
Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Table Text Block]	The following information applies to common stock purchase warrants outstanding and exercisable at December 31, 2015: Warrants Outstanding Warrants Exercisable Shares Weighted- Average Remaining Contractual Term Weighted- Average Exercise Price Shares Weighted- Average Exercise Price $ 0.01 – $20.00 94,108 6.8 $ 15.54 94,108 $ 15.54 $ 20.01 – $30.00 29,743 6.1 $ 24.52 27,743 $ 24.72 $ 30.01 – $40.00 628 1.6 $ 40.00 628 $ 40.00 $ 40.01 - $50.00 6,253 3.1 $ 48.36 4,253 $ 48.49 $ 50.01 – $60.00 543 1.9 $ 60.00 543 $ 60.00 $ >60.00 8,092 4.2 $ 2,823.67 6,547 $ 1,675.28 139,367 6.3 $ 182.26 133,822 $ 99.98

NOTE 13 - COMMITMENTS AND CON31

NOTE 13 - COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Approximate annual future minimum lease obligations under non-cancelable operating lease agreements as of December 31, 2015 are as follows: Year ending December 31, 2016 $ 43,830

NOTE 14 - INCOME TAXES (Tables)

NOTE 14 - INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The difference between income tax expense computed by applying the federal statutory corporate tax rate and actual income tax expense is as follows: 2015 2014 Income taxes using U.S. federal statutory rate $ (575,971 ) $ (766,194 ) State income taxes, net of federal benefit (47,571 ) (90,051 ) Return to Provision adjustments 116,025 - Stock Option Expirations - 66,043 Net Operating Loss adjustments - (144,824 ) Nontaxable Gain on Derivative Instrument 8,101 933,477 Change in Valuation Allowance 493,123 1,549 Other 6,293 - $ - $ —
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	At December 31, 2015, the significant components of the deferred tax assets (liabilities) are summarized below: 2015 2014 Deferred tax assets: Stock Based Compensation $ 5,099,422 $ 4,794,777 Net Operating Losses 36,323,004 36,117,831 Other 24,774 41,469 Total deferred tax assets 41,447,200 40,954,077 Deferred tax liabilities: - — Total deferred tax liabilities - — Valuation allowance 41,447,200 40,954,077 Net deferred tax assets $ - $ —

NOTE 15 - FAIR VALUE MEASUREM33

NOTE 15 - FAIR VALUE MEASUREMENT (Tables)	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities as of December 31, 2015: Warrant Liability Debt Derivative Balance, December 31, 2013 $ 146,855 $ 256,956 Total (gains) losses Initial fair value of debt derivative at note issuance — 1,443,708 Initial fair value of derivative relating to reset warrants — — Mark-to-market at December 31, 2014: 3,065 (429,018 ) Transfers out of Level 3 upon increase in authorized shares — — Transfers out of Level 3 upon conversion and settlement of notes — (680,295 ) Balance, December 31, 2014 $ 149,920 $ 591,351 Total (gains) losses Initial fair value of debt derivative at note issuance — 1,097,379 Mark-to-market at December 31, 2015: (137,711 ) 122,616 Transfers out of Level 3 upon conversion or payoff of notes payable — (1,399,628 ) Balance, December 31, 2015 $ 12,209 $ 411,718 Net gain (loss) for the period included in earnings relating to the liabilities held at December 31, 2015 $ 137,711 $ (122,616 )

NOTE 16 - SUBSEQUENT EVENTS (Ta

NOTE 16 - SUBSEQUENT EVENTS (Tables)	12 Months Ended
	Dec. 31, 2015
NOTE 16 - SUBSEQUENT EVENTS (Tables) [Line Items]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Approximate annual future minimum lease obligations under non-cancelable operating lease agreements as of December 31, 2015 are as follows: Year ending December 31, 2016 $ 43,830
Building and Building Improvements [Member]
NOTE 16 - SUBSEQUENT EVENTS (Tables) [Line Items]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Approximate annual future minimum lease obligations under this non-cancelable facilities operating lease agreement as of December 31, 2015 are as follows: Year ending December 31, 2016 $ 87,674 2017 87,674 2018 87,674 2019 58,450 Total $ 321,472

NOTE 1 - SIGNIFICANT ACCOUNTI35

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	Oct. 12, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2012
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Stockholders' Equity Note, Stock Split	1-for-1,000
Deferred Revenue, Current (in Dollars)		$ 71,961	$ 13,000
Allowance for Doubtful Accounts Receivable, Current (in Dollars)		$ 0	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number (in Shares)		555,820	66,933	23,921
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number (in Shares)		511,660
Research and Development Expense (in Dollars)		$ 10,000	$ 66,420
U.S. Stem Cell Clinic, LLC [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Equity Method Investment, Ownership Percentage		33.00%
Full-Time Employees [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Number of Employees		4
Part-Time Employees [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Number of Employees		1
Accounts Receivable [Member] | Credit Concentration Risk [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage		66.00%	55.00%
Accounts Receivable [Member] | Credit Concentration Risk [Member] | Customer One [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage		32.00%	38.00%
Accounts Receivable [Member] | Credit Concentration Risk [Member] | Customer Two [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage		18.00%	17.00%
Accounts Receivable [Member] | Credit Concentration Risk [Member] | Customer Three [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage		16.00%
Minimum [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Property, Plant and Equipment, Useful Life		3 years
Maximum [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Property, Plant and Equipment, Useful Life		15 years

NOTE 1 - SIGNIFICANT ACCOUNTI36

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,372,727	1,119,349
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	677,540	901,796
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	555,820	66,933
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	139,367	150,620

NOTE 2 - GOING CONCERN AND MA37

NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net Income (Loss) Attributable to Parent	$ (1,641,880)	$ (2,253,511)
Net Cash Provided by (Used in) Operating Activities	$ (844,690)	$ (1,108,647)

NOTE 3 - INVESTMENTS (Details)

NOTE 3 - INVESTMENTS (Details) - USD ($)	12 Months Ended		196 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015
NOTE 3 - INVESTMENTS (Details) [Line Items]
Payments for (Proceeds from) Investments	$ 10,000	$ 49,714
Income (Loss) from Equity Method Investments	38,542	(9,117)
Investments	$ 89,139	40,597	$ 89,139
U.S. Stem Cell Clinic, LLC [Member]
NOTE 3 - INVESTMENTS (Details) [Line Items]
Equity Method Investment, Ownership Percentage	33.00%		33.00%
Payments for (Proceeds from) Investments	$ 59,714
Income (Loss) from Equity Method Investments	38,542	(9,117)	$ 29,425
Investments	89,139		89,139
Accounts Receivable, Net	5,946	0	$ 5,946
Revenues	$ 182,922	$ 0

NOTE 4 - PROPERTY AND EQUIPME39

NOTE 4 - PROPERTY AND EQUIPMENT (Details) - Schedule of Property and Equipment - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Schedule of Property and Equipment [Abstract]
Laboratory and medical equipment	$ 353,253	$ 352,358
Furniture, fixtures and equipment	130,410	125,634
Computer equipment	48,788	47,647
Leasehold improvements	362,046	362,046
	894,497	887,685
Less accumulated depreciation and amortization	(880,325)	(874,999)
	$ 14,172	$ 12,686

NOTE 5 - ACCRUED EXPENSES (Deta

NOTE 5 - ACCRUED EXPENSES (Details)	Nov. 04, 2015shares	Oct. 07, 2015shares	Dec. 31, 2015USD ($)shares	Dec. 31, 2014USD ($)shares
NOTE 5 - ACCRUED EXPENSES (Details) [Line Items]
Gains (Losses) on Extinguishment of Debt			$ 2,620,233	$ 2,498,676
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | shares	3,411	34,522
Relief of Accounts Payable [Member]
NOTE 5 - ACCRUED EXPENSES (Details) [Line Items]
Gains (Losses) on Extinguishment of Debt			513,940
Common Stock Issued in Settlement of Accounts Payable, Accrued Expenses and Accrued Interest [Member]
NOTE 5 - ACCRUED EXPENSES (Details) [Line Items]
Gains (Losses) on Extinguishment of Debt			$ 144,669	$ 120,656
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | shares			67,944	48,585
Common Stock Issued in Settlement of Guarantor Fees [Member]
NOTE 5 - ACCRUED EXPENSES (Details) [Line Items]
Gains (Losses) on Extinguishment of Debt			$ 791,024
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | shares			24,353
Debt Conversion, Converted Instrument, Amount			$ 961,124
Debt Instrument, Term			5 years
Extinguishment of Debt, Amount			$ 624,737
Settlement of 2000 Patent License Agreement [Member]
NOTE 5 - ACCRUED EXPENSES (Details) [Line Items]
Number of Patents Licensed				2
Gains (Losses) on Extinguishment of Debt				$ 2,122,130

NOTE 5 - ACCRUED EXPENSES (De41

NOTE 5 - ACCRUED EXPENSES (Details) - Schedule of Accrued Liabilities - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Schedule of Accrued Liabilities [Abstract]
Amounts payable to the Guarantors of the Company’s loan agreement with Bank of America and Seaside Bank, including fees and interest	$ 64,199	$ 1,533,217
Interest payable on notes payable	467,664	685,575
Vendor accruals and other	147,244	120,836
Employee commissions, compensation, etc.	47,644	33,987
	$ 726,751	$ 2,373,615

NOTE 6 - STANDBY EQUITY DISTR42

NOTE 6 - STANDBY EQUITY DISTRIBUTION AGREEMENT (Details)	Nov. 02, 2011USD ($)
Standby Equity Distribution Agreement [Abstract]
Proceeds from Contributions from Affiliates	$ 1,000,000
Period for Whcih Funding is Provided	24 months
Related Party Transaction, Description of Transaction	For each share of the Company common stock purchased under the Agreement, Greystone will pay eighty percent (80%) of the average of the lowest daily volume weighted average price for five consecutive trading days immediately preceding Advance Notice (the “Valuation Period”) commencing the date an Advance Notice (the “Advance Notice”) is delivered to Greystone in a manner provided by the Agreement.
Description of Purchase Price Adjustment Under Equity Line	the parties to the Equity Line agreed that the Purchase Price be adjusted to seventy-five percent (75%) of the lowest daily volume weighted average price of the Common Stock as quoted by Bloomberg, LP, during the five (5) consecutive Trading Days (as such term is defined in the Equity Line) immediately subsequent to the date of the relevant Advance Notice.

NOTE 7 - STOCK PURCHASE AGREE43

NOTE 7 - STOCK PURCHASE AGREEMENT (Details) - USD ($)	Oct. 23, 2014	Dec. 31, 2015	Dec. 31, 2014
NOTE 7 - STOCK PURCHASE AGREEMENT (Details) [Line Items]
Common Stock, Par or Stated Value Per Share		$ 0.001	$ 0.001
Stock Issued During Period, Shares, New Issues			42,067
Stock Issued During Period, Value, New Issues		$ 582,808	$ 479,625
Stock Purchase Agreement [Member]
NOTE 7 - STOCK PURCHASE AGREEMENT (Details) [Line Items]
Stock Repurchase Program, Authorized Amount	$ 3,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001
Stock Repurchase Program, Period in Force	24 months
Purchase Commitment, Description	From time to time over the term of the Purchase Agreement, commencing on the trading day immediately following the date on which the initial registration statement was declared effective by the Securities and Exchange Commission (the “Commission”), the Company may provide the Investor with a draw down notice to purchase a specified dollar amount of Shares, with each draw down subject to certain limitations.The Company may not deliver any Draw Down Notice to the Investor if the Initial Purchase Price with respect to the Shares subject to such Draw Down Notice is less than $2.50 as of the date the applicable Draw Down Notice is received by the Investor (the “Draw Down Exercise Date”).The applicable Initial Purchase Price, the “Initial Purchase Price”, is defined as a price equal to 93% of the lowest of (i) the arithmetic average of the three lowest daily volume weighted average prices for the Company’s common stock (the “VWAP”) during the 10 consecutive trading days ending on the trading day immediately preceding the applicable Draw Down Exercise Date, (ii) the arithmetic average of the three lowest closing sale prices for the Company’s common stock during the 10 consecutive trading days ending on the trading day immediately preceding the applicable Draw Down Exercise Date and (iii) the closing sale price for the Company’s common stock on the trading day immediately preceding the applicable Draw Down Exercise Date.
Stock Issued During Period, Shares, New Issues		7,852	12,000
Stock Issued During Period, Value, New Issues		$ 61,270
Stock Purchase Agreement, Magna Equities II, LLC [Member]
NOTE 7 - STOCK PURCHASE AGREEMENT (Details) [Line Items]
Stock Issued During Period, Shares, New Issues		87,812
Stock Issued During Period, Value, New Issues		$ 521,538

NOTE 8 - NOTES PAYABLE (Details

NOTE 8 - NOTES PAYABLE (Details)

Jan. 07, 2016USD ($)

Dec. 31, 2015USD ($)$ / shares

Dec. 17, 2015USD ($)

Dec. 03, 2015USD ($)

Nov. 19, 2015USD ($)

Nov. 04, 2015USD ($)

Oct. 07, 2015USD ($)

Aug. 06, 2015

Jun. 01, 2015USD ($)

Jul. 31, 2015USD ($)

Mar. 08, 2016USD ($)

Mar. 31, 2016

Dec. 31, 2015USD ($)$ / shares

Dec. 31, 2014USD ($)$ / shares

Oct. 25, 2010USD ($)

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Notes Payable

$ 1,841,434

$ 1,841,434

$ 1,870,972

Derivative Liability, Current

423,927

423,927

741,271

Debt Conversion, Original Debt, Amount

$ 5,860

$ 100,000

Debt Instrument, Unamortized Discount

249,205

249,205

339,160

Gains (Losses) on Extinguishment of Debt

2,620,233

2,498,676

Amortization of Debt Discount (Premium)

818,404

546,970

Notes Payable, Other Payables [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Unamortized Discount

240,521

240,521

Convertible Debt [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Gains (Losses) on Extinguishment of Debt

$ 10,221

Fair Value Assumptions, Expected Dividend Rate

0.00%

Fair Value Assumptions, Expected Volatility Rate

164.06%

Fair Value Assumptions, Risk Free Interest Rate

0.87%

Convertible Debt [Member] | Principal [Member] | Subsequent Event [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Debt Conversion, Original Debt, Amount

$ 91,170

Convertible Debt [Member] | Interest [Member] | Subsequent Event [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Debt Conversion, Original Debt, Amount

$ 2,649

Seaside National Bank and Trust [Member] | Notes Payable to Banks [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Face Amount

$ 980,000

Debt Instrument, Interest Rate, Stated Percentage

4.25%

Notes Payable

$ 980,000

$ 980,000

$ 980,000

Seaside National Bank and Trust [Member] | Notes Payable to Banks [Member] | Subsequent Event [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Maturity Date

Jan. 11, 2018

Hunton & Williams Notes [Member] | Notes Payable, Other Payables [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

8.00%

8.00%

8.00%

Number of Outstanding Notes Payable

2

2

2

Notes Payable

$ 384,972

$ 384,972

$ 384,972

Debt Instrument, Payment Terms

payable in one balloon payment upon the date the Noteholder provides written demand, however the Company is not obligated to make payments until the Northstar (or successor) Loan is paid off.

payable in one balloon payment upon the date the Noteholder provides written demand, however the Company is not obligated to make payments until the Northstar (or successor) Loan is paid off.

Hunton & Williams Note #1 [Member] | Notes Payable, Other Payables [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Notes Payable

61,150

$ 61,150

$ 61,150

Hunton & Williams Note #2 [Member] | Notes Payable, Other Payables [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Notes Payable

323,822

323,822

323,822

Asher Notes Payable [Member] | Convertible Debt [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Face Amount

$ 180,000

$ 180,000

$ 334,000

Debt Instrument, Interest Rate, Stated Percentage

8.00%

8.00%

8.00%

Debt Instrument, Maturity Date

Feb. 6, 2016

Aug. 12, 2015

Notes Payable

$ 0

$ 0

$ 151,000

Debt Instrument, Term

9 months

9 months

Debt Instrument, Convertible, Terms of Conversion Feature

convertible into shares of common stock, at Asher’s option, at a 45% discount to the average of the three lowest closing bid prices of the shares of common stock during the 10 trading day period prior to conversion.

The Notes are convertible into common stock, at Asher’s option, at a 45% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion.

Derivative Liability, Current

$ 149,770

Embedded Derivative, Fair Value of Embedded Derivative Liability

211,575

$ 211,575

566,294

Debt Issuance Cost

15,000

Asher Notes Payable [Member] | Convertible Debt [Member] | Conversion of Debt, Notes and Accrued Interest #1 [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Debt Conversion, Original Debt, Amount

151,000

Asher Notes Payable [Member] | Convertible Debt [Member] | Conversion of Debt, Notes and Accrued Interest #2 [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Debt Conversion, Original Debt, Amount

180,000

Daniel James Management Notes Payable [Member] | Convertible Debt [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Face Amount

$ 125,000

$ 125,000

$ 135,000

Debt Instrument, Interest Rate, Stated Percentage

9.50%

9.50%

Debt Instrument, Maturity Date

Oct. 29, 2016

Nov. 30, 2015

Notes Payable

$ 75,000

$ 75,000

$ 75,000

Debt Instrument, Term

1 year

1 year

Debt Instrument, Convertible, Terms of Conversion Feature

convertible into common stock, at holder’s option, at a 47% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion

The Daniel Notes are convertible into common stock, at holder’s option, at a 47% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion.

Derivative Liability, Current

120,263

$ 120,263

$ 95,866

Embedded Derivative, Fair Value of Embedded Derivative Liability

238,443

238,443

236,211

Daniel James Management Notes Payable [Member] | Convertible Debt [Member] | Subsequent Event [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Face Amount

$ 25,000

Debt Instrument, Interest Rate, Stated Percentage

9.50%

Debt Instrument, Maturity Date

Jan. 7, 2017

Debt Instrument, Convertible, Terms of Conversion Feature

The Note is convertible into common stock, at Daniel James Management Inc.’s option, at a 47% discount to the lowest daily closing trading price of the common stock during the 10 trading day period prior to conversion.

Daniel James Management Notes Payable [Member] | Convertible Debt [Member] | Conversion of Debt, Notes and Accrued Interest #1 [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Debt Conversion, Original Debt, Amount

75,000

Daniel James Management Notes Payable [Member] | Convertible Debt [Member] | Conversion of Debt, Notes and Accrued Interest #2 [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Debt Conversion, Original Debt, Amount

50,000

Fourth Man, LLC Notes Payable [Member] | Convertible Debt [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Face Amount

$ 150,000

$ 150,000

$ 100,000

Debt Instrument, Interest Rate, Stated Percentage

9.50%

9.50%

Debt Instrument, Maturity Date

Dec. 2, 2016

Aug. 28, 2015

Notes Payable

$ 77,450

$ 77,450

$ 75,000

Debt Instrument, Term

1 year

1 year

Debt Instrument, Convertible, Terms of Conversion Feature

The Notes are convertible into shares of common stock, at Fourth Man’s option, at a 47% discount to the lowest closing bid price of the common stock during the 10 trading day period prior to conversion.

The Notes are convertible into common stock, at Fourth Man’s option, at a 47% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion.

Derivative Liability, Current

126,825

$ 126,825

$ 93,505

Embedded Derivative, Fair Value of Embedded Derivative Liability

356,225

356,225

168,501

Fourth Man, LLC Notes Payable [Member] | Convertible Debt [Member] | Conversion of Debt, Notes and Accrued Interest #1 [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Debt Conversion, Original Debt, Amount

75,000

Fourth Man, LLC Notes Payable [Member] | Convertible Debt [Member] | Conversion of Debt, Notes and Accrued Interest #2 [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Debt Conversion, Original Debt, Amount

72,550

Magna Group Notes Payable [Member] | Convertible Debt [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Face Amount

$ 110,000

$ 110,000

$ 307,500

Debt Instrument, Interest Rate, Stated Percentage

12.00%

12.00%

12.00%

Debt Instrument, Maturity Date

Nov. 7, 2015

Aug. 1, 2016

Aug. 7, 2015

Notes Payable

$ 125,000

$ 125,000

$ 205,000

Debt Instrument, Convertible, Terms of Conversion Feature

This amendment also changes the conversion price of the notes from $10.35 to the lesser of a) $6.00 or b) a 40% discount from the lowest trading price in the five trading days prior to conversion.

The convertible note is convertible at any time, in whole or in part, at Magna’s option into shares of the Company’s common stock at a the lower of i) 60% discount to the lowest trading price of the common stock during the 5 trading day period prior to conversion or ii) $0.70 per share.

The Convertible Note is convertible at any time, in whole or in part, at Magna’s option into shares of Company common stock at a fixed conversion price of $10.35 per share, subject to adjustment pursuant to the “full ratchet” and standard anti-dilution provisions contained in the Convertible Note. This resulted in an embedded derivatives liability as a result of these anti-dilution provision. This conversion price represents a discount of approximately 45% from the lowest trading price the Company common stock during the five trading days prior to October 7, 2014, the date the Company issued the Convertible Note to Magna.

Derivative Liability, Current

164,600

$ 164,600

$ 252,211

Embedded Derivative, Fair Value of Embedded Derivative Liability

291,136

291,136

472,702

Debt Conversion, Original Debt, Amount

205,000

Debt Instrument, Unamortized Discount

$ 102,500

Debt Instrument, Description

$40,000 of the outstanding principal amount of the Convertible Note (together with any accrued and unpaid interest with respect to such portion of the principal amount) will be automatically extinguished upon the filing of the registration statement, following the closing of the Securities Purchase Agreement. In addition, $62,500 of the outstanding principal amount of the Convertible Note (together with any accrued and unpaid interest with respect to such portion of the principal amount) will be automatically extinguished if (i) the registration statement is declared effective by the SEC on or prior to the earlier of (A) the 120th calendar day after October 7, 2014 and (B) the fifth business day after the date we are notified by the Securities and Exchange Commission, or the Commission, that the registration statement will not be reviewed or will not be subject to further review, and this prospectus is available for use by Magna for the resale by Magna of all of the shares of our common stock issued or issuable upon conversion of the Convertible Note and (ii) no event of default under the Convertible Note or an event that with the passage of time or giving of notice would constitute an event of default under the Convertible Note has occurred on or prior to such date. On November 21, 2014, the Company filed its registration statement and on December 22, 2014, was declared effective.

Debt Instrument, Increase (Decrease), Other, Net

$ (102,500)

Debt Instrument, Original Issue Discount, Percentage

33.33%

Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares

$ 10.35

Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt

$ 128,624

Proceeds from Convertible Debt

100,000

Magna Group Note Payable #2 [Member] | Convertible Debt [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Face Amount

$ 15,000

Debt Instrument, Interest Rate, Stated Percentage

12.00%

Debt Instrument, Maturity Date

Aug. 1, 2016

Debt Instrument, Convertible, Terms of Conversion Feature

The convertible note is convertible at any time, in whole or in part, at Magna’s option into shares of the Company’s common stock at the lower of 60% of the lowest sale price of the Company’s common stock during five trading days preceding conversion date or $0.70 per share (subject to adjustment).

Debt Instrument, Description

Company entered into a securities purchase agreement with Magna Equities II, LLC. The purchase agreement provides that Magna shall purchase from the Company a senior convertible note with an initial principal amount of $262,500, subject to filing and becoming effective registration statement is declared effective by the SEC.

Power Up Lending Group Notes Payable [Member] | Notes Payable, Other Payables [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Notes Payable

194,235

194,235

0

Power Up Lending Group Notes Payable [Member] | Convertible Debt [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Face Amount

$ 202,500

$ 243,000

Notes Payable

194,235

194,235

Debt Instrument, Payment Terms

Under the terms of the agreements, the Company is required to make daily payments equal to $1,378 for 147 business days.

Under the terms of the agreements, the Company is required to make daily payments equal to the greater of $1,464 or 20% of the Company’s daily cash or monetary sales receipts over the term of the agreements (ranging from 126 to 189 business days).

Debt Instrument, Unamortized Discount

51,164

51,164

Proceeds from Convertible Debt

$ 150,000

$ 180,000

Debt Instrument, Fee Amount

4,500

3,590

Net Proceeds from Convertible Debt

53,642

Gains (Losses) on Extinguishment of Debt

$ (8,679)

Equipment Finance Lease [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

7.75%

Notes Payable

4,777

4,777

0

Debt Instrument, Term

48 months

Debt Instrument, Periodic Payment

$ 116

Former Officers and Directors, Non-Related Notes Payable [Member] | Notes Payable, Other Payables [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Face Amount

$ 1,500,000

Note Payable, Settlement of Subordinated Debt, Accrued Interest and Guarantor Fees [Member] | Notes Payable, Other Payables [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Face Amount

$ 1,697,762

Debt Instrument, Interest Rate, Stated Percentage

0.00%

Debt Instrument, Maturity Date

Jun. 1, 2020

Debt Instrument, Term

5 years

Debt Instrument, Unamortized Discount

319,385

$ 368,615

319,385

Gains (Losses) on Extinguishment of Debt

1,169,058

Debt Instrument, Periodic Payment

$ 75,000

Debt Instrument, Frequency of Periodic Payment

four semi-annual

Debt Instrument, Date of First Required Payment

Dec. 31, 2015

Debt Instrument, Imputed Interest, Stated Percentage

5.00%

Amortization of Debt Discount (Premium)

49,537

Note Payable, Settlement of Subordinated Debt, Accrued Interest and Guarantor Fees [Member] | Notes Payable, Other Payables [Member] | Principal [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Extinguishment of Debt, Amount

$ 1,500,000

Note Payable, Settlement of Subordinated Debt, Accrued Interest and Guarantor Fees [Member] | Notes Payable, Other Payables [Member] | Interest [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Extinguishment of Debt, Amount

373,469

Note Payable, Settlement of Subordinated Debt, Accrued Interest and Guarantor Fees [Member] | Notes Payable, Other Payables [Member] | Guarantor Fees [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Extinguishment of Debt, Amount

$ 624,737

Asher, Daniel, Fourth Man LLC and Magna Notes [Member] | Convertible Debt [Member] | Embedded Derivative Financial Instruments [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Embedded Derivative, Fair Value of Embedded Derivative Liability

411,718

411,718

Debt Instrument, Unamortized Discount

$ 1,097,379

1,097,379

Proceeds from Convertible Debt

568,464

Interest Expense, Debt

$ 528,915

Fair Value Assumptions, Expected Dividend Rate

0.00%

Minimum [Member] | Daniel James Management Notes Payable [Member] | Convertible Debt [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Minimum [Member] | Fourth Man, LLC Notes Payable [Member] | Convertible Debt [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

8.00%

8.00%

8.00%

Minimum [Member] | Power Up Lending Group Notes Payable [Member] | Convertible Debt [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Term

126 days

Interest Expense, Debt

$ 44,226

Minimum [Member] | Former Officers and Directors, Non-Related Notes Payable [Member] | Notes Payable, Other Payables [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

4.75%

Minimum [Member] | Asher, Daniel, Fourth Man LLC and Magna Notes [Member] | Convertible Debt [Member] | Embedded Derivative Financial Instruments [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Fair Value Assumptions, Expected Volatility Rate

111.98%

Fair Value Assumptions, Risk Free Interest Rate

0.17%

Fair Value Assumptions, Expected Term

9 months

Share Price (in Dollars per share) | $ / shares

$ 1.10

$ 1.10

Maximum [Member] | Daniel James Management Notes Payable [Member] | Convertible Debt [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

9.50%

Maximum [Member] | Fourth Man, LLC Notes Payable [Member] | Convertible Debt [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

9.50%

9.50%

9.50%

Maximum [Member] | Power Up Lending Group Notes Payable [Member] | Convertible Debt [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Term

189 days

Maximum [Member] | Former Officers and Directors, Non-Related Notes Payable [Member] | Notes Payable, Other Payables [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Maximum [Member] | Asher, Daniel, Fourth Man LLC and Magna Notes [Member] | Convertible Debt [Member] | Embedded Derivative Financial Instruments [Member]

NOTE 8 - NOTES PAYABLE (Details) [Line Items]

Fair Value Assumptions, Expected Volatility Rate

175.10%

Fair Value Assumptions, Risk Free Interest Rate

0.57%

Fair Value Assumptions, Expected Term

1 year

Share Price (in Dollars per share) | $ / shares

$ 12.70

$ 12.70

NOTE 8 - NOTES PAYABLE (Detai45

NOTE 8 - NOTES PAYABLE (Details) - Schedule of Notes Payable - USD ($)	Dec. 31, 2015	Dec. 31, 2014
NOTE 8 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	$ 1,841,434	$ 1,870,972
Less unamortized debt discount	(249,205)	(339,160)
Total notes payable net of unamortized debt discount	1,592,229	1,531,812
Less current portion	(608,502)	(1,531,812)
Long term portion	983,727	0
Notes Payable, Other Payables [Member]
NOTE 8 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Less unamortized debt discount	(240,521)
Seaside National Bank and Trust [Member] | Notes Payable to Banks [Member]
NOTE 8 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	980,000	980,000
Hunton & Williams Notes [Member] | Notes Payable, Other Payables [Member]
NOTE 8 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	384,972	384,972
Asher Notes Payable [Member] | Convertible Debt [Member]
NOTE 8 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	0	151,000
Daniel James Management Notes Payable [Member] | Convertible Debt [Member]
NOTE 8 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	75,000	75,000
Fourth Man, LLC Notes Payable [Member] | Convertible Debt [Member]
NOTE 8 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	77,450	75,000
Magna Group Notes Payable [Member] | Convertible Debt [Member]
NOTE 8 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	125,000	205,000
Less unamortized debt discount		(102,500)
Power Up Lending Group Notes Payable [Member] | Notes Payable, Other Payables [Member]
NOTE 8 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	194,235	0
Power Up Lending Group Notes Payable [Member] | Convertible Debt [Member]
NOTE 8 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	194,235
Less unamortized debt discount	(51,164)
Equipment Finance Lease [Member]
NOTE 8 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	$ 4,777	$ 0

NOTE 9 - RELATED PARTY TRANSA46

NOTE 9 - RELATED PARTY TRANSACTIONS (Details) - USD ($)

Nov. 06, 2015

Nov. 04, 2015

Oct. 07, 2015

Oct. 02, 2015

Apr. 03, 2015

Nov. 03, 2014

Oct. 03, 2014

Jul. 01, 2014

Jun. 20, 2014

Apr. 02, 2014

Dec. 24, 2013

Sep. 30, 2013

Oct. 01, 2012

Sep. 21, 2012

Mar. 30, 2012

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Sep. 30, 2015

May. 19, 2014

Aug. 01, 2013

Feb. 28, 2013

Feb. 29, 2012

NOTE 9 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Due to Related Parties, Current

$ 106,505

$ 98,759

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

3,411

34,522

Debt Conversion, Original Debt, Amount

$ 5,860

$ 100,000

Class of Warrant or Rights, Granted (in Shares)

2,072

57,582

Preferred Stock, Shares Authorized (in Shares)

20,000,000

20,000,000

20,000,000

20,000,000

Stock Issued During Period, Shares, Other (in Shares)

11,918

Stock Issued During Period, Value, Other

$ 2,819,704

$ 1,071,155

Notes Payable, Related Parties

1,465,022

2,021,059

Notes Payable, Related Parties, Current

1,727,022

$ 2,383,059

Series A Preferred Stock [Member]

NOTE 9 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Preferred Stock, Voting Rights

modify the voting rights of the Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stock holders to 25 votes per share on matters to be voted on by the common stock holders and all prior and subsequent payments of interest will be in common stock

U.S. Stem Cell Clinic, LLC [Member]

NOTE 9 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Debt Instrument, Face Amount

$ 30,000

Debt Instrument, Interest Rate, Stated Percentage

4.00%

Debt Instrument, Maturity Date

Nov. 3, 2017

Director [Member]

NOTE 9 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

270,800

Debt Conversion, Original Debt, Amount

$ 465,200

Debt Instrument, Face Amount

$ 50,000

Class of Warrant or Rights, Granted (in Shares)

13,064

Ms. Murphy [Member]

NOTE 9 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

7.00%

7.00%

Notes Payable, Related Parties

$ 50,000

$ 50,000

Dr. Ahn [Member]

NOTE 9 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

4,046

Debt Conversion, Original Debt, Amount

$ 125,000

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Debt Instrument, Maturity Date

Oct. 15, 2015

Oct. 15, 2015

Notes Payable, Related Parties, Current

$ 0

$ 0

$ 125,000

Immediate Family Member of Management or Principal Owner [Member]

NOTE 9 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Related Party Transaction, Purchases from Related Party

242,271

Related Party Transaction, Amounts of Transaction

302,899

Accounts Payable, Related Parties, Current

$ 74,793

$ 23,862

Settlement of Related Party Advances and Outstanding Accounts Payable [Member]

NOTE 9 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

10,232

Debt Conversion, Original Debt, Amount

$ 298,759

Settlement of Related Party Advances [Member]

NOTE 9 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

3,411

Debt Conversion, Original Debt, Amount

$ 5,860

Common Stock Issued in Settlement of Related Party Notes and Advances Payable [Member] | Director [Member]

NOTE 9 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

10,333

Notes Payable, Other Payables [Member] | Affiliated Entity [Member]

NOTE 9 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

3,916

8,772

10,000

Debt Conversion, Original Debt, Amount

$ 85,447

$ 100,000

$ 210,000

Debt Instrument, Face Amount

$ 544,267

Debt Instrument, Payment Terms

Company is obligated to issue additional preferred stock equal in lieu of payment of cash of accrued and unpaid interest on each six month anniversary of the effective date (October 1, 2012).

agreed to extend until May 1, 2012 the initial payment date for any and all required monthly under the Note, such that the first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012, and to waive any and all defaults and/or events of default under the Note with respect to such payments. The Company did not make the required payment, and as a result, was in default of the revised agreement The Company renegotiated the terms of the Note and Northstar agreed to suspend the requirement of principal payments by the Company and allow payment of interest-only in common stock.

Class of Warrant or Rights, Granted (in Shares)

15,000

5,000

Debt Instrument, Debt Default, Description of Violation or Event of Default

entered into a limited waiver and forbearance agreement providing a recapitalized new note balance comprised of all sums due Northstar with a maturity date extended perpetually. The Company agreed to issue 5,000,000 shares of Series A Convertible Preferred Stock and 10,000 of common stock in exchange for $210,000 as payment towards outstanding debt, default interest, penalties, professional fees outstanding and due Northstar. In addition, the Company executed a security agreement granting Northstar a lien on all patents, patent applications, trademarks, service marks, copyrights and intellectual property rights of any nature, as well as the results of all clinical trials, know-how for preparing Myoblasts, old and new clinical data, existing approved trials, all right and title to Myoblasts, clinical trial protocols and other property rights.In addition, the Company granted Northstar a perpetual license on products as described for resale, relicensing and commercialization outside the United States. In connection with the granted license, Northstar shall pay the Company a royalty of up to 8% on revenues generated.

PercentageOfRevenuesToBeReceivedAsRoyalty

8.00%

Debt Instrument, Interest Rate, Stated Percentage

12.85%

7.00%

Notes Payable, Related Parties

262,000

$ 362,000

Notes Payable, Other Payables [Member] | Affiliated Entity [Member] | Series A Preferred Stock [Member]

NOTE 9 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

5,000,000

Stock Issued During Period, Value, Other

$ 274,050

Notes Payable, Other Payables [Member] | Affiliated Entity [Member] | Series A Preferred Stock [Member] | Settlement of Forbearance Agreement, Penalty [Member]

NOTE 9 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Stock Issued During Period, Shares, Other (in Shares)

15,000,000

Notes Payable, Other Payables [Member] | Director [Member]

NOTE 9 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Debt Instrument, Payment Terms

The Company is not obligated to make payment until Northstar (or successor) Loan is paid off.

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Notes Payable, Related Parties

0

$ 465,240

Notes Payable, Other Payables [Member] | Ms. Murphy [Member]

NOTE 9 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Notes Payable, Related Parties

50,000

50,000

Notes Payable, Other Payables [Member] | Chief Scientific Officer [Member]

NOTE 9 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Notes Payable, Related Parties

287,772

299,465

Notes Payable, Other Payables [Member] | Interest [Member] | Affiliated Entity [Member]

NOTE 9 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

4,156

1,363

515

275

Debt Conversion, Original Debt, Amount

$ 12,705

$ 12,635

$ 12,705

$ 12,635

Note Payable #1 [Member] | Notes Payable, Other Payables [Member] | Chief Executive Officer [Member]

NOTE 9 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

5.00%

Notes Payable, Related Parties

252,250

331,354

Repayments of Related Party Debt

79,104

186,779

Note Payable #1 [Member] | Notes Payable, Other Payables [Member] | Chief Scientific Officer [Member]

NOTE 9 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Debt Instrument, Face Amount

$ 125,000

Debt Instrument, Interest Rate, Stated Percentage

5.00%

Notes Payable, Related Parties, Current

0

Repayments of Related Party Debt

97,718

$ 27,282

Note Payable #1 [Member] | Subordinated Debt [Member] | Director [Member]

NOTE 9 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Notes Payable, Related Parties

$ 100,000

Debt Instrument, Maturity Date

Nov. 30, 2012

Note Payable #2 [Member] | Notes Payable, Other Payables [Member] | Chief Executive Officer [Member]

NOTE 9 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Debt Instrument, Face Amount

$ 375,000

Debt Instrument, Interest Rate, Stated Percentage

5.00%

Notes Payable, Related Parties

375,000

$ 375,000

Note Payable #2 [Member] | Notes Payable, Other Payables [Member] | Chief Scientific Officer [Member]

NOTE 9 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Debt Instrument, Face Amount

$ 300,000

Debt Instrument, Interest Rate, Stated Percentage

5.00%

Debt Instrument, Maturity Date

Jan. 1, 2015

Notes Payable, Related Parties, Current

287,772

Repayments of Related Party Debt

11,693

535

Note Payable #2 [Member] | Subordinated Debt [Member] | Director [Member]

NOTE 9 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Notes Payable, Related Parties

$ 140,000

Debt Instrument, Maturity Date

Jun. 4, 2011

Related Party Debt [Member] | Common Stock Issued in Settlement of Related Party Notes and Advances Payable [Member] | Director [Member]

NOTE 9 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Debt Conversion, Original Debt, Amount

$ 298,386

Settlement of Related Party Advances [Member] | Common Stock Issued in Settlement of Related Party Notes and Advances Payable [Member] | Director [Member]

NOTE 9 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Debt Conversion, Original Debt, Amount

2,000

Interest [Member] | Dr. Ahn [Member]

NOTE 9 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Debt Conversion, Original Debt, Amount

36,832

Interest [Member] | Common Stock Issued in Settlement of Related Party Notes and Advances Payable [Member] | Director [Member]

NOTE 9 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Debt Conversion, Original Debt, Amount

$ 112,954

Note Payable #3 [Member] | Notes Payable, Other Payables [Member] | Chief Executive Officer [Member]

NOTE 9 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Debt Instrument, Face Amount

$ 500,000

Debt Instrument, Interest Rate, Stated Percentage

5.00%

Notes Payable, Related Parties

$ 500,000

$ 500,000

Debt Instrument, Maturity Date

Jan. 1, 2015

NOTE 9 - RELATED PARTY TRANSA47

NOTE 9 - RELATED PARTY TRANSACTIONS (Details) - Schedule of Related Party Notes Payable - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Related Party Transaction [Line Items]
Notes Payable, Related Party	$ 1,465,022	$ 2,021,059
Director [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	0	465,240
Ms. Murphy [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	50,000	50,000
Ms. Murphy [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	50,000	50,000
Chief Executive Officer [Member] | Note Payable #1 [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	252,250	331,354
Chief Executive Officer [Member] | Note Payable #2 [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	375,000	375,000
Chief Executive Officer [Member] | Note Payable #3 [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	500,000	500,000
Chief Scientific Officer [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	$ 287,772	$ 299,465

NOTE 10 - DERIVATIVE LIABILIT48

NOTE 10 - DERIVATIVE LIABILITIES (Details) - USD ($)	Oct. 01, 2012	Sep. 21, 2012	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2012
NOTE 10 - DERIVATIVE LIABILITIES (Details) [Line Items]
Class of Warrant or Rights, Granted (in Shares)			2,072	57,582
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)			$ 182.26	$ 170	$ 220
Warrant [Member] | Embedded Derivative Financial Instruments [Member]
NOTE 10 - DERIVATIVE LIABILITIES (Details) [Line Items]
Embedded Derivative, Fair Value of Embedded Derivative, Net (in Dollars)			$ 12,209
Fair Value Assumptions, Expected Dividend Rate			0.00%
Fair Value Assumptions, Expected Volatility Rate			178.53%
Fair Value Assumptions, Risk Free Interest Rate			2.09%
Fair Value Assumptions, Expected Term			6 years 9 months
Derivative, Gain (Loss) on Derivative, Net (in Dollars)			$ 137,710
Debt [Member] | Embedded Derivative Financial Instruments [Member]
NOTE 10 - DERIVATIVE LIABILITIES (Details) [Line Items]
Embedded Derivative, Fair Value of Embedded Derivative, Net (in Dollars)			$ 411,718
Fair Value Assumptions, Expected Dividend Rate			0.00%
Fair Value Assumptions, Expected Volatility Rate			178.53%
Derivative, Gain (Loss) on Derivative, Net (in Dollars)			$ 122,615
Fair Value of Common Stock (in Dollars per share)			$ 0.875
Affiliated Entity [Member] | Notes Payable, Other Payables [Member]
NOTE 10 - DERIVATIVE LIABILITIES (Details) [Line Items]
Class of Warrant or Rights, Granted (in Shares)	15,000	5,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 14
Warrants, Term of Warrants	10 years
Minimum [Member] | Debt [Member] | Embedded Derivative Financial Instruments [Member]
NOTE 10 - DERIVATIVE LIABILITIES (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate			0.49%
Fair Value Assumptions, Expected Term			153 days
Maximum [Member] | Debt [Member] | Embedded Derivative Financial Instruments [Member]
NOTE 10 - DERIVATIVE LIABILITIES (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate			0.65%
Fair Value Assumptions, Expected Term			335 days

NOTE 11 - STOCKHOLDERS' EQUITY

NOTE 11 - STOCKHOLDERS' EQUITY (Details) - USD ($)	Nov. 04, 2015	Oct. 12, 2015	Oct. 07, 2015	Oct. 02, 2015	Aug. 17, 2015	Apr. 03, 2015	Mar. 19, 2015	Nov. 03, 2014	Oct. 03, 2014	Apr. 02, 2014	Dec. 24, 2013	Sep. 30, 2013	Oct. 01, 2012	Sep. 21, 2012	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Oct. 23, 2014	May. 19, 2014	Dec. 31, 2012	Aug. 17, 2012
NOTE 11 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized															20,000,000	20,000,000	20,000,000		20,000,000
Preferred Stock, Shares Issued															20,000,000	20,000,000
Common Stock, Shares Authorized															2,000,000,000	2,000,000,000	950,000,000		2,000,000,000
Stockholders' Equity, Reverse Stock Split		1-for-1,000
Common Stock, Par or Stated Value Per Share (in Dollars per share)															$ 0.001	$ 0.001
Adjustments to Additional Paid in Capital, Stock Split (in Dollars)																$ 580,852
Debt Conversion, Converted Instrument, Shares Issued	3,411		34,522
Debt Conversion, Original Debt, Amount (in Dollars)	$ 5,860		$ 100,000
Gains (Losses) on Extinguishment of Debt (in Dollars)															$ 2,620,233	2,498,676
Stock Issued During Period, Shares, Settlement of Litigation							6,650								6,650
Gain (Loss) Related to Litigation Settlement (in Dollars)															$ (59,850)	$ 0
Stock Issued During Period, Shares, New Issues																42,067
Stock Issued During Period, Value, New Issues (in Dollars)															$ 582,808	$ 479,625
Class of Warrant or Rights, Granted															2,072	57,582
Stock Issued During Period, Shares, Other																11,918
Stock Issued During Period, Value, Other (in Dollars)															$ 2,819,704	$ 1,071,155
Stock Issued During Period, Shares, Issued for Services																3,840
Stock Issued During Period, Value, Issued for Services (in Dollars)																$ 183,991
Stock Purchase Agreement, Magna Equities II, LLC [Member]
NOTE 11 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, New Issues															87,812
Stock Issued During Period, Value, New Issues (in Dollars)															$ 521,538
Stock Purchase Agreement [Member]
NOTE 11 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Common Stock, Par or Stated Value Per Share (in Dollars per share)																		$ 0.001
Stock Issued During Period, Shares, New Issues															7,852	12,000
Stock Issued During Period, Value, New Issues (in Dollars)															$ 61,270
Class of Warrant or Rights, Granted															1,444
Series A Convertible Preferred Stock [Member]
NOTE 11 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized																				20,000,000	5,000,000
Preferred Stock, Voting Rights					Each share of preferred stock is convertible into equal number of common shares at the option of the holder; entitled to 20 votes on all matters presented to be voted by the holders of common stock; upon event of liquidation, entitled to amount equal to stated value plus any accrued and unpaid dividends or other fees before distribution to junior securities												the parties have determined to modify the voting rights of the Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stock holders to 25 votes per share on matters to be voted on by the common stock holders
Preferred Stock, Shares Issued																	20,000,000
Director [Member]
NOTE 11 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued	270,800
Debt Conversion, Original Debt, Amount (in Dollars)	$ 465,200
Class of Warrant or Rights, Granted								13,064
Common Stock [Member]
NOTE 11 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, Settlement of Litigation															6,650
Stock Repurchased During Period, Shares															85,211
Treasury Stock Acquired, Average Cost Per Share (in Dollars per share)															$ 2.61
Stock Issued During Period, Shares, New Issues															95,664	42,067
Stock Issued During Period, Value, New Issues (in Dollars)															$ 96	$ 42
Stock Issued During Period, Shares, Other															1,037,645	48,585
Stock Issued During Period, Value, Other (in Dollars)															$ 1,038	$ 48
Stock Issued During Period, Shares, Issued for Services																3,840
Stock Issued During Period, Value, Issued for Services (in Dollars)																$ 4
Common Stock Issued in Settlement of Accounts Payable and Accrued Expenses [Member]
NOTE 11 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Gains (Losses) on Extinguishment of Debt (in Dollars)																$ 120,656
Stock Issued During Period, Shares, Other																48,585
Stock Purchase Agreement [Member]
NOTE 11 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, Other																12,000
Common Stock Issued in Settlement of Accounts Payable and Accrued Expenses [Member]
NOTE 11 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued															62,425
Debt Conversion, Original Debt, Amount (in Dollars)															$ 211,546
Gains (Losses) on Extinguishment of Debt (in Dollars)															144,669
Common Stock Issued in Settlement of Guarantor Fees [Member]
NOTE 11 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Gains (Losses) on Extinguishment of Debt (in Dollars)															$ 791,024
Stock Issued During Period, Shares, Other															24,353
Stock Issued During Period, Value, Other (in Dollars)															$ 961,125
Common Stock Issued in Settlement of Notes Payable and Accrued Interest [Member]
NOTE 11 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued																83,236
Debt Conversion, Original Debt, Amount (in Dollars)																$ 1,974,917
Gains (Losses) on Extinguishment of Debt (in Dollars)																255,890
Notes Payable, Other Payables [Member] | Affiliated Entity [Member]
NOTE 11 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued											3,916	8,772					10,000
Debt Conversion, Original Debt, Amount (in Dollars)											$ 85,447	$ 100,000					$ 210,000
Class of Warrant or Rights, Granted													15,000	5,000
Notes Payable, Other Payables [Member] | Interest [Member] | Affiliated Entity [Member]
NOTE 11 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued				4,156		1,363			515	275
Debt Conversion, Original Debt, Amount (in Dollars)				$ 12,705		$ 12,635			$ 12,705	$ 12,635
Fair Value, Inputs, Level 3 [Member] | Embedded Derivative Financial Instruments [Member] | Debt [Member]
NOTE 11 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued															763,434
Debt Conversion, Original Debt, Amount (in Dollars)															$ 949,017
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers out of Level 3 (in Dollars)															$ (1,399,628)	$ (680,295)

NOTE 12 - STOCK OPTIONS AND W50

NOTE 12 - STOCK OPTIONS AND WARRANTS (Details) - USD ($)	Nov. 02, 2015	Aug. 24, 2015	Feb. 02, 2015	Nov. 03, 2014	Aug. 01, 2014	May. 12, 2014	Mar. 10, 2014	Feb. 24, 2014	Nov. 30, 2014	Dec. 31, 2015	Dec. 31, 2014	Aug. 04, 2014	Apr. 01, 2013	Dec. 31, 2012
NOTE 12 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)										489,116	43,148
Share-based Compensation (in Dollars)										$ 1,152,195	$ 537,606
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars)										$ 473,898
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition										1 year
Class of Warrant or Rights, Granted (in Shares)										2,072	57,582
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)										$ 182.26	$ 170			$ 220
Gains (Losses) on Extinguishment of Debt (in Dollars)										$ 2,620,233	$ 2,498,676
Director [Member]
NOTE 12 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Rights, Granted (in Shares)				13,064
Warrants, Term of Warrants				3 years
Warrants, Fair Value of Warrants, Granted (in Dollars)				$ 148,517
Fair Value Assumptions, Expected Dividend Rate				0.00%
Fair Value Assumptions, Expected Volatility Rate				152.87%
Fair Value Assumptions, Risk Free Interest Rate				0.96%
Employee Stock Option [Member]
NOTE 12 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation (in Dollars)										$ 1,156,435	$ 537,606
Warrants [Member]
NOTE 12 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Rights, Granted (in Shares)										1,444	41,582
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)										$ 11.27
Warrants, Term of Warrants										10 years
Bioheart 2013 Omnibus Equity Compensation Plan [Member]
NOTE 12 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)	500,000,000											100,000	50,000
Bioheart 2013 Omnibus Equity Compensation Plan [Member] | Employee Stock Option [Member] | Officer [Member]
NOTE 12 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)	467,016							15,000
Share-based Compensation Arranagement by Share-based Payment Award, Options, Exercise Price (in Dollars per share)	$ 1.713							$ 19
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	vesting immediately							vesting at 25% immediately and the remainder over approximately 42 months
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years							10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Fair Value Grants in Period (in Dollars)	$ 738,405							$ 282,597
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%							0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	160.66%							163.63%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.57%							2.75%
Bioheart 2013 Omnibus Equity Compensation Plan [Member] | Employee Stock Option [Member] | Officers [Member]
NOTE 12 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)	15,000							4,800
Share-based Compensation Arranagement by Share-based Payment Award, Options, Exercise Price (in Dollars per share)	$ 6.24							$ 19
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	vesting over four years on each anniversary							vesting immediately
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years							10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Fair Value Grants in Period (in Dollars)	$ 23,512							$ 90,431
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%							0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	160.66%							163.63%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.93%							2.75%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Bioheart 2013 Omnibus Equity Compensation Plan [Member] | Employee Stock Option [Member] | Officers and Employees [Member]
NOTE 12 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)				700	15,000	4,848
Share-based Compensation Arranagement by Share-based Payment Award, Options, Exercise Price (in Dollars per share)				$ 19.32	$ 26.94	$ 27.20
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights				vesting at 25% each year over four years at anniversary	vesting at 25% immediately and 75% over three years at anniversary	vesting over four years at anniversary
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				10 years	10 years	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Fair Value Grants in Period (in Dollars)				$ 12,739	$ 391,798	$ 130,135
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate				0.00%	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate				152.87%	168.62%	161.36%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate				2.36%	2.52%	2.66%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				4 years		4 years
Bioheart 2013 Omnibus Equity Compensation Plan [Member] | Employee Stock Option [Member] | Director [Member]
NOTE 12 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)			7,000	2,800
Share-based Compensation Arranagement by Share-based Payment Award, Options, Exercise Price (in Dollars per share)			$ 11.16	$ 19.32
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights			vesting immediately	vesting immediately
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			10 years	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Fair Value Grants in Period (in Dollars)			$ 121,735	$ 54,957
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate			0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate			142.65%	152.87%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate			1.68%	2.36%
Options Issued to Consultant [Member] | Bioheart 2013 Omnibus Equity Compensation Plan [Member] | Employee Stock Option [Member]
NOTE 12 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)		100
Share-based Compensation Arranagement by Share-based Payment Award, Options, Exercise Price (in Dollars per share)		$ 5.31
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights		vesting immediately
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		4 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Fair Value Grants in Period (in Dollars)		$ 347
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate		0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		129.01%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		1.39%
Revenue Share Agreement [Member]
NOTE 12 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights							2,000 warrants vesting 90 days from the effective date, 2,000 vesting on each anniversary date for three years.
Class of Warrant or Rights, Granted (in Shares)							8,000		4,000		12,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)							$ 21.70		$ 15.70
Warrants, Term of Warrants							4 years		4 years
Allocated Share-based Compensation Expense (in Dollars)							$ 103,238		$ 54,146		$ 54,146
Convertible Debt [Member]
NOTE 12 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Rights, Granted (in Shares)										628
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)										$ 40
Warrants, Term of Warrants										3 years
Warrants, Fair Value of Warrants, Granted (in Dollars)										$ 14,886
Fair Value Assumptions, Expected Dividend Rate										0.00%
Fair Value Assumptions, Expected Volatility Rate										164.06%
Fair Value Assumptions, Risk Free Interest Rate										0.87%
Gains (Losses) on Extinguishment of Debt (in Dollars)										$ 10,221
Intellectual Property [Member]
NOTE 12 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Rights, Granted (in Shares)											4,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)											$ 48.10
Warrants, Term of Warrants											4 years
Allocated Share-based Compensation Expense (in Dollars)											$ 32,878

NOTE 12 - STOCK OPTIONS AND W51

NOTE 12 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Option Activity - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Schedule of Option Activity [Abstract]
Options Outstanding	66,933		23,921
Options Outstanding, Weighted-Average Exercise Price (in Dollars per share)	$ 56		$ 150
Options Outstanding, Weighted-Average Remaining Contractual Term	9 years 219 days	8 years 328 days	9 years
Options exercisable at December 31, 2015	511,660
Options exercisable at December 31, 2015 (in Dollars per share)	$ 5.60
Options exercisable at December 31, 2015	9 years 255 days
Available for grant at December 31, 2015	7,383,070
Options Granted	489,116	43,148
Options Granted, Weighted-Average Exercise Price (in Dollars per share)	$ 1.98	$ 23
Options Granted, Weighted-Average Remaining Contractual Term	10 years	10 years
Options Exercised	0	0
Options Forfeited/Expired	(229)	(136)
Options Forfeited/Expired, Weighted-Average Exercise Price (in Dollars per share)	$ 5,103.28	$ 5,200
Options Outstanding	555,820	66,933
Options Outstanding, Weighted-Average Exercise Price (in Dollars per share)	$ 6.43	$ 56

NOTE 12 - STOCK OPTIONS AND W52

NOTE 12 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Options Outstanding and Exercisable by Exercise Price Range	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding | shares	555,820
Options Outstanding, Weighted-Average Exercise Price | $ / shares	$ 6.43
Options Exercisable | shares	511,660
Options Outstanding, Weighted-Average Remaining Contractual Term	9 years 219 days
Options Exercisable, Weighted-Average Exercise Price | $ / shares	$ 5.60
Options, Exercise Price Range, $0.00-$20.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding | shares	534,706
Options Outstanding, Weighted-Average Exercise Price | $ / shares	$ 3.32
Options Exercisable | shares	501,682
Options Outstanding, Weighted-Average Remaining Contractual Term	9 years 255 days
Options Exercisable, Weighted-Average Exercise Price | $ / shares	$ 2.72
Options, Exercise Price Range, $20.01-$30.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding | shares	19,849
Options Outstanding, Weighted-Average Exercise Price | $ / shares	$ 26.96
Options Exercisable | shares	8,713
Options Outstanding, Weighted-Average Remaining Contractual Term	8 years 6 months
Options Exercisable, Weighted-Average Exercise Price | $ / shares	$ 26.94
Options, Exercise Price Range, $30.01-$100.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding | shares	300
Options Outstanding, Weighted-Average Exercise Price | $ / shares	$ 70
Options Exercisable | shares	300
Options Outstanding, Weighted-Average Remaining Contractual Term	5 years 255 days
Options Exercisable, Weighted-Average Exercise Price | $ / shares	$ 70
Options, Exercise Price Range, $100.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding | shares	965
Options Outstanding, Weighted-Average Exercise Price | $ / shares	$ 1,288.36
Options Exercisable | shares	965
Options Outstanding, Weighted-Average Remaining Contractual Term	4 years
Options Exercisable, Weighted-Average Exercise Price | $ / shares	$ 1,288.36

NOTE 12 - STOCK OPTIONS AND W53

NOTE 12 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Activity - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Schedule of Warrants Activity [Abstract]
Warrants Outstanding	150,620		118,134
Warrants Outstanding, Weighted-Average Exercise Price	$ 170		$ 220
Warrants Outstanding, Weighted-Average Remaining Contractual Term	6 years 109 days	6 years 219 days	6 years 109 days
Exercisable at December 31, 2015	133,822
Exercisable at December 31, 2015	$ 99.98
Exercisable at December 31, 2015	6 years 109 days
Warrants Issued	2,072	57,582
Warrants Issued, Weighted-Average Exercise Price	$ 19.98	$ 20
Warrants Issued, Weighted-Average Remaining Contractual Term	8 years 65 days	8 years 73 days
Warrants Exercised	0	(11,918)
Warrants Exercised, Weighted-Average Exercise Price	$ 0	$ 10
Warrants Expired	(13,325)	(13,178)
Warrants Expired, Weighted-Average Exercise Price	$ 24	$ 80
Warrants Outstanding	139,367	150,620
Warrants Outstanding, Weighted-Average Exercise Price	$ 182.26	$ 170

NOTE 12 - STOCK OPTIONS AND W54

NOTE 12 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
NOTE 12 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding	139,367	150,620		118,134
Warrants Outstanding, Weighted-Average Remaining Contractual Term	6 years 109 days	6 years 219 days	6 years 109 days
Warrants Outstanding, Weighted-Average Exercise Price	$ 182.26	$ 170		$ 220
Warrants Exercisable	133,822
Warrants Exercisable, Weighted-Average Exercise Price	$ 99.98
Class of Warrants or Rights, Exercise Price Range, $0.01-$20.00 [Member]
NOTE 12 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding	94,108
Warrants Outstanding, Weighted-Average Remaining Contractual Term	6 years 292 days
Warrants Outstanding, Weighted-Average Exercise Price	$ 15.54
Warrants Exercisable	94,108
Warrants Exercisable, Weighted-Average Exercise Price	$ 15.54
Class of Warrants or Rights, Exercise Price Range, $20.01-$30.00 [Member]
NOTE 12 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding	29,743
Warrants Outstanding, Weighted-Average Remaining Contractual Term	6 years 36 days
Warrants Outstanding, Weighted-Average Exercise Price	$ 24.52
Warrants Exercisable	27,743
Warrants Exercisable, Weighted-Average Exercise Price	$ 24.72
Class of Warrants or Rights, Exercise Price Range, $30.01-$40.00 [Member]
NOTE 12 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding	628
Warrants Outstanding, Weighted-Average Remaining Contractual Term	1 year 219 days
Warrants Outstanding, Weighted-Average Exercise Price	$ 40
Warrants Exercisable	628
Warrants Exercisable, Weighted-Average Exercise Price	$ 40
Class of Warrants or Rights, Exercise Price Range, $40.01-$50.00 [Member]
NOTE 12 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding	6,253
Warrants Outstanding, Weighted-Average Remaining Contractual Term	3 years 36 days
Warrants Outstanding, Weighted-Average Exercise Price	$ 48.36
Warrants Exercisable	4,253
Warrants Exercisable, Weighted-Average Exercise Price	$ 48.49
Class of Warrants or Rights, Exercise Price Range, $50.01-$60.00 [Member]
NOTE 12 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding	543
Warrants Outstanding, Weighted-Average Remaining Contractual Term	1 year 328 days
Warrants Outstanding, Weighted-Average Exercise Price	$ 60
Warrants Exercisable	543
Warrants Exercisable, Weighted-Average Exercise Price	$ 60
Class of Warrants or Rights, Exercise Price Range, Greater than $60.00 [Member]
NOTE 12 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding	8,092
Warrants Outstanding, Weighted-Average Remaining Contractual Term	4 years 73 days
Warrants Outstanding, Weighted-Average Exercise Price	$ 2,823.67
Warrants Exercisable	6,547
Warrants Exercisable, Weighted-Average Exercise Price	$ 1,675.28

NOTE 13 - COMMITMENTS AND CON55

NOTE 13 - COMMITMENTS AND CONTINGENCIES (Details) - USD ($)

Nov. 02, 2015

Jul. 28, 2015

Jun. 01, 2015

Mar. 19, 2015

Nov. 10, 2014

Jul. 28, 2014

Mar. 10, 2014

Nov. 30, 2014

Jul. 31, 2013

Nov. 02, 2015

Jun. 30, 2015

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2012

NOTE 13 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Operating Leases, Rent Expense

$ 131,257

$ 128,136

Class of Warrant or Rights, Granted (in Shares)

2,072

57,582

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 182.26

$ 170

$ 220

Accrued Royalties

$ 2,122,130

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

489,116

43,148

Stock Issued During Period, Shares, Settlement of Litigation (in Shares)

6,650

6,650

Loss Contingency, Damages Sought, Value

$ 2,300,000

Gain (Loss) Related to Litigation Settlement

$ (59,850)

$ 0

Building [Member]

NOTE 13 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Lease Expiration Date

Jul. 31, 2016

Revenue Share Agreement [Member]

NOTE 13 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Other Commitments, Description

Profits are divided on a fifty/fifty basis with distribution within 10 days of the accounting for patients and physician training and 30 day with sales of equipment and kits. In November 2014, the Company terminated the Agreement.

Class of Warrant or Rights, Granted (in Shares)

8,000

4,000

12,000

Warrants, Term of Warrants

4 years

4 years

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 21.70

$ 15.70

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights

2,000 warrants vesting 90 days from the effective date, 2,000 vesting on each anniversary date for three years.

Allocated Share-based Compensation Expense

$ 103,238

$ 54,146

$ 54,146

Annual Salary [Member] | Chief Executive Officer [Member]

NOTE 13 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Salaries, Wages and Officers' Compensation

$ 525,000

Annual Salary [Member] | Chief Scientific Officer [Member]

NOTE 13 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Salaries, Wages and Officers' Compensation

$ 250,000

Incentive Bonus [Member] | Chief Executive Officer [Member]

NOTE 13 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Salaries, Wages and Officers' Compensation

$ 500,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

291,885

10,000

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

10 years

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

4 years

Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award

cashless exercise provision at an exercise price equal to the five day average closing price of the Company’s common stock as of August 1, 2014. The cash bonus may be paid in the form a six month promissory note.

Share-based Compensation Arranagement by Share-based Payment Award, Options, Exercise Price (in Dollars per share)

$ 1.713

Incentive Bonus [Member] | Chief Scientific Officer [Member]

NOTE 13 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

175,131

5,000

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

10 years

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

4 years

Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award

cashless exercise provision at an exercise price equal to the five day average closing price of the Company’s common stock as of August 1, 2014. The cash bonus may be paid in the form a six month promissory note.

Share-based Compensation Arranagement by Share-based Payment Award, Options, Exercise Price (in Dollars per share)

$ 1.713

Note Payable, Settlement of Subordinated Debt, Accrued Interest and Guarantor Fees [Member] | Notes Payable, Other Payables [Member]

NOTE 13 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Gain (Loss) Related to Litigation Settlement

$ 1,169,058

Debt Instrument, Face Amount

$ 1,697,762

Debt Instrument, Term

5 years

Debt Instrument, Interest Rate, Stated Percentage

0.00%

Minimum [Member] | Incentive Bonus [Member] | Chief Executive Officer [Member]

NOTE 13 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Salaries, Wages and Officers' Compensation

150,000

Minimum [Member] | Incentive Bonus [Member] | Chief Scientific Officer [Member]

NOTE 13 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Salaries, Wages and Officers' Compensation

$ 100,000

Maximum [Member] | Incentive Bonus [Member] | Chief Executive Officer [Member]

NOTE 13 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Salaries, Wages and Officers' Compensation

$ 500,000

Maximum [Member] | Incentive Bonus [Member] | Chief Scientific Officer [Member]

NOTE 13 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Salaries, Wages and Officers' Compensation

$ 300,000

$ 300,000

NOTE 13 - COMMITMENTS AND CON56

NOTE 13 - COMMITMENTS AND CONTINGENCIES (Details) - Schedule of Future Minimum Rental Payments for Operating Leases	Dec. 31, 2015USD ($)
Schedule of Future Minimum Rental Payments for Operating Leases [Abstract]
2,016	$ 43,830

NOTE 14 - INCOME TAXES (Details

NOTE 14 - INCOME TAXES (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
NOTE 14 - INCOME TAXES (Details) [Line Items]
Annual Limit of Corporation to Reduce Tax Liability	Section 382 of the Internal Revenue Code of 1986 (the “Code”) imposes an annual limit on the ability of a corporation that undergoes a greater than 50% ownership change to use its net operating loss carry forwards to reduce its tax liability
Operating Loss Carryforwards, Limitations on Use	If in the future the Company issues common stock or additional equity instruments convertible in common shares which result in an ownership change exceeding the 50% limitation threshold imposed by section 382 of the Code, the Company’s net operating loss carryforwards may be significantly limited as to the amount of use in a particular years.
Domestic Tax Authority [Member]
NOTE 14 - INCOME TAXES (Details) [Line Items]
Operating Loss Carryforwards	$ 96.5	$ 95.8
State and Local Jurisdiction [Member]
NOTE 14 - INCOME TAXES (Details) [Line Items]
Operating Loss Carryforwards	$ 97.5	$ 95.8
Minimum [Member] | Domestic Tax Authority [Member]
NOTE 14 - INCOME TAXES (Details) [Line Items]
Operating Loss Carryforwards, Expiration Year	2,020
Minimum [Member] | State and Local Jurisdiction [Member]
NOTE 14 - INCOME TAXES (Details) [Line Items]
Operating Loss Carryforwards, Expiration Year	2,020
Maximum [Member] | Domestic Tax Authority [Member]
NOTE 14 - INCOME TAXES (Details) [Line Items]
Operating Loss Carryforwards, Expiration Year	2,035
Maximum [Member] | State and Local Jurisdiction [Member]
NOTE 14 - INCOME TAXES (Details) [Line Items]
Operating Loss Carryforwards, Expiration Year	2,035

NOTE 14 - INCOME TAXES (Detai58

NOTE 14 - INCOME TAXES (Details) - Schedule of Effective Income Tax Rate Reconciliation - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Schedule of Effective Income Tax Rate Reconciliation [Abstract]
Income taxes using U.S. federal statutory rate	$ (575,971)	$ (766,194)
State income taxes, net of federal benefit	(47,571)	(90,051)
Return to Provision adjustments	116,025	0
Stock Option Expirations	0	66,043
Net Operating Loss adjustments	0	(144,824)
Nontaxable Gain on Derivative Instrument	8,101	933,477
Change in Valuation Allowance	493,123	1,549
Other	6,293	0
	$ 0	$ 0

NOTE 14 - INCOME TAXES (Detai59

NOTE 14 - INCOME TAXES (Details) - Schedule of Deferred Tax Assets and Liabilities - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets:
Stock Based Compensation	$ 5,099,422	$ 4,794,777
Net Operating Losses	36,323,004	36,117,831
Other	24,774	41,469
Total deferred tax assets	41,447,200	40,954,077
Total deferred tax liabilities	0	0
Valuation allowance	41,447,200	40,954,077
Net deferred tax assets	$ 0	$ 0

NOTE 15 - FAIR VALUE MEASUREM60

NOTE 15 - FAIR VALUE MEASUREMENT (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Derivative Liability, Current	$ 423,927	$ 741,271
Percentage of Stock Price Decrease	(22.00%)
Fair Value Measurements, Valuation Processes, Description	A 10 percent change in pricing inputs and changes in volatilities and correlation factors would result in less than a $70,000 change in our Level 3 fair value.

NOTE 15 - FAIR VALUE MEASUREM61

NOTE 15 - FAIR VALUE MEASUREMENT (Details) - Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation - Fair Value, Inputs, Level 3 [Member] - Embedded Derivative Financial Instruments [Member] - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Warrant [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	$ 149,920	$ 146,855
Net gain (loss) for the period included in earnings relating to the liabilities held at December 31, 2015	137,711
Total (gains) losses
Initial fair value of derivative	0
Mark-to-market	(137,711)	3,065
Transfers out of Level 3	0
Balance	12,209	149,920
Debt [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	591,351	256,956
Net gain (loss) for the period included in earnings relating to the liabilities held at December 31, 2015	(122,616)
Total (gains) losses
Initial fair value of derivative	1,097,379	1,443,708
Mark-to-market	122,616	(429,018)
Transfers out of Level 3	(1,399,628)	(680,295)
Balance	$ 411,718	$ 591,351

NOTE 16 - SUBSEQUENT EVENTS (De

NOTE 16 - SUBSEQUENT EVENTS (Details) - USD ($)

Feb. 04, 2016

Jan. 11, 2016

Jan. 07, 2016

Dec. 03, 2015

Nov. 04, 2015

Oct. 07, 2015

Feb. 29, 2016

Jul. 31, 2013

Mar. 08, 2016

Mar. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Dec. 12, 2014

Oct. 25, 2010

NOTE 16 - SUBSEQUENT EVENTS (Details) [Line Items]

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

3,411

34,522

Debt Conversion, Original Debt, Amount

$ 5,860

$ 100,000

Stock Issued During Period, Shares, Issued for Services (in Shares)

3,840

Stock Issued During Period, Value, Issued for Services

$ 183,991

Director [Member]

NOTE 16 - SUBSEQUENT EVENTS (Details) [Line Items]

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

270,800

Debt Conversion, Original Debt, Amount

$ 465,200

Debt Instrument, Face Amount

$ 50,000

Director [Member] | Subsequent Event [Member]

NOTE 16 - SUBSEQUENT EVENTS (Details) [Line Items]

Repayments of Related Party Debt

$ 100,000

Building [Member]

NOTE 16 - SUBSEQUENT EVENTS (Details) [Line Items]

Lease Expiration Date

Jul. 31, 2016

Building [Member] | Subsequent Event [Member]

NOTE 16 - SUBSEQUENT EVENTS (Details) [Line Items]

Lease Expiration Date

Aug. 31, 2019

Operating Leases, Rent Expense, Minimum Rentals

$ 7,306

Security Deposit Liability

$ 11,072

Settlement of Services [Member] | Subsequent Event [Member]

NOTE 16 - SUBSEQUENT EVENTS (Details) [Line Items]

Stock Issued During Period, Shares, Issued for Services (in Shares)

16,753

Stock Issued During Period, Value, Issued for Services

$ 13,110

Convertible Debt [Member] | Subsequent Event [Member]

NOTE 16 - SUBSEQUENT EVENTS (Details) [Line Items]

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

625,352

Convertible Debt [Member] | Principal [Member] | Subsequent Event [Member]

NOTE 16 - SUBSEQUENT EVENTS (Details) [Line Items]

Debt Conversion, Original Debt, Amount

$ 91,170

Convertible Debt [Member] | Interest [Member] | Subsequent Event [Member]

NOTE 16 - SUBSEQUENT EVENTS (Details) [Line Items]

Debt Conversion, Original Debt, Amount

$ 2,649

Seaside National Bank and Trust [Member] | Notes Payable to Banks [Member]

NOTE 16 - SUBSEQUENT EVENTS (Details) [Line Items]

Debt Instrument, Face Amount

$ 980,000

Debt Instrument, Interest Rate, Stated Percentage

4.25%

Seaside National Bank and Trust [Member] | Notes Payable to Banks [Member] | Subsequent Event [Member]

NOTE 16 - SUBSEQUENT EVENTS (Details) [Line Items]

Debt Instrument, Maturity Date, Description

extend the maturity date to January 11, 2018

Debt Instrument, Maturity Date

Jan. 11, 2018

Related Party Debt [Member] | Subsequent Event [Member]

NOTE 16 - SUBSEQUENT EVENTS (Details) [Line Items]

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

14,606

Magna Equities Notes Payable [Member] | Convertible Debt [Member]

NOTE 16 - SUBSEQUENT EVENTS (Details) [Line Items]

Debt Instrument, Face Amount

$ 262,500

Debt Instrument, Interest Rate, Stated Percentage

12.00%

Debt Instrument, Maturity Date

Dec. 3, 2016

Debt Instrument, Convertible, Terms of Conversion Feature

The Note is convertible into common stock, at Magna’s option, at the lower of i) 40% discount to the lowest sales price of the common stock during the 5 trading day period prior to conversion or ii) $0.70. In the event the Company prepays the Note in full, the Company is required to pay off all principal at 140%, interest and any other amounts.

Common Stock, Number of Shares Registered (in Shares)

341,718

Magna Equities Notes Payable [Member] | Convertible Debt [Member] | Conversion of Debt, Notes and Accrued Interest #1 [Member]

NOTE 16 - SUBSEQUENT EVENTS (Details) [Line Items]

Debt Instrument, Face Amount

$ 110,000

Magna Equities Notes Payable [Member] | Convertible Debt [Member] | Conversion of Debt, Notes and Accrued Interest #2 [Member]

NOTE 16 - SUBSEQUENT EVENTS (Details) [Line Items]

Debt Instrument, Face Amount

$ 262,500

Daniel James Management Notes Payable [Member] | Convertible Debt [Member]

NOTE 16 - SUBSEQUENT EVENTS (Details) [Line Items]

Debt Instrument, Face Amount

$ 125,000

$ 135,000

Debt Instrument, Interest Rate, Stated Percentage

9.50%

Debt Instrument, Maturity Date

Oct. 29, 2016

Nov. 30, 2015

Debt Instrument, Convertible, Terms of Conversion Feature

convertible into common stock, at holder’s option, at a 47% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion

The Daniel Notes are convertible into common stock, at holder’s option, at a 47% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion.

Daniel James Management Notes Payable [Member] | Convertible Debt [Member] | Subsequent Event [Member]

NOTE 16 - SUBSEQUENT EVENTS (Details) [Line Items]

Debt Instrument, Face Amount

$ 25,000

Debt Instrument, Interest Rate, Stated Percentage

9.50%

Debt Instrument, Maturity Date

Jan. 7, 2017

Debt Instrument, Convertible, Terms of Conversion Feature

The Note is convertible into common stock, at Daniel James Management Inc.’s option, at a 47% discount to the lowest daily closing trading price of the common stock during the 10 trading day period prior to conversion.

Debt Instrument, Debt Default, Description of Violation or Event of Default

In the event the Company prepays the Note in full, the Company is required to pay off all principal at 150%, interest and any other amounts.

Daniel James Management Notes Payable [Member] | Convertible Debt [Member] | Conversion of Debt, Notes and Accrued Interest #1 [Member]

NOTE 16 - SUBSEQUENT EVENTS (Details) [Line Items]

Debt Conversion, Original Debt, Amount

$ 75,000

Daniel James Management Notes Payable [Member] | Convertible Debt [Member] | Conversion of Debt, Notes and Accrued Interest #2 [Member]

NOTE 16 - SUBSEQUENT EVENTS (Details) [Line Items]

Debt Conversion, Original Debt, Amount

$ 50,000

NOTE 16 - SUBSEQUENT EVENTS (63

NOTE 16 - SUBSEQUENT EVENTS (Details) - Schedule of Future Minimum Rental Payments for Operating Leases - USD ($)	Feb. 04, 2016	Dec. 31, 2015
NOTE 16 - SUBSEQUENT EVENTS (Details) - Schedule of Future Minimum Rental Payments for Operating Leases [Line Items]
2,016		$ 43,830
Building [Member] | Subsequent Event [Member]
NOTE 16 - SUBSEQUENT EVENTS (Details) - Schedule of Future Minimum Rental Payments for Operating Leases [Line Items]
2,016	$ 87,674
2,017	87,674
2,018	87,674
2,019	58,450
Total	$ 321,472